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INTRODUCTION 
Human health and an individual’s susceptibility to a disease are determined by 
genetic variation, as well as by variation in the influencing environment. 
Epidemiologic research deals with “the distribution and determinants of health-
related states or events in specified populations, and the application of this 
study to control of health problems” (Last, Spasoff et al. 2001).  
In developed countries, the majority of morbidity and mortality consists of 
common yet complex diseases such as cardiovascular disease, cancer, and 
autoimmune disorders as well as metabolic conditions such as obesity and 
diabetes, not to mention psychiatric and neurological disorders (Zhang, De et 
al.). Such complex traits are characterized by the interplay of multiple genes 
and multiple environmental factors.  
During the last decades, epidemiologic research has more and more focused 
on unraveling the genetic background of diseases – with limited success for 
complex traits. After more than 50 years of research still, a big part of heritability 
is missed or not understood. Problems with study designs, methods of data 
analysis and interpretation result in consistent errors in studies and a lack of 
replication across big data sets (Ioannidis 2005).  
The close-up on strategies and approaches in general and human genome 
epidemiology in this work will help to understand challenges of previous, 
present, and future research. The brief introduction to molecular epidemiology 
focuses on epigenetics, a young field of research that is dealing with 
mechanisms that modify gene expression due to environmental changes 
(among other roles). 
The ‘‘early origins hypothesis’’ postulates that nutrition and a range of other 
environmental factors during prenatal and early postnatal development program 
cellular plasticity through epigenetic changes (Dolinoy and Jirtle 2008). 
Moreover, the epigenome is influenced by environmental factors during the 
entire life. This alters susceptibilities to adult cardiovascular disease, type 2 
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diabetes, obesity, and other chronic diseases independently of the genetic 
predisposition. Previous findings indicate that genetic polymorphisms are more 
likely to induce a shift in between the working capacities of all networks that are 
involved in the etiology of a complex disease rather than de-/increasing the 
overall risk for the disease (Stoger 2008).  
A case study on the UCP1 network in adaptive thermogenesis in the metabolic 
syndrome is an excellent example to discuss uncertainties of association 
studies and to compare results with evidence on epigenetic regulation in the 
same network. Epigenetic markers might be able to increase the quality of 
human genome epidemiology on complex diseases. Furthermore, validated 
epigenetic biomarkers might increase the predictive value of genetic tests and 
in matters of public health, they might help to unravel problems of complexity. 
.  
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ENVIRONMENT, GENES & THE PHENOTYPE 
For a human being, “environment” consists of all external surroundings shaping 
the course of life. The functionality of the living organism depends on the 
interaction of (more or less) essential physical, chemical, and biological agents, 
but also social, cultural, and political factors (Davis 1989). “Environmental 
health is the totality of influences on human health and disease that are 
determined by environmental factors (1947). 
The international Epidemiological Association defines environment as: 
"All that which is external to the human host”. […] “The environment 
provides the food people eat, the water they drink, the air they 
breathe, the energy they command, the plagues and pests they 
combat and the mountains, seas, lakes, streams, plants and animals 
that they enjoy and depend upon” (Last, Spasoff et al. 2001). 
According to this definition, “environment” includes anything that is not genetic. 
The genetic information of an organism for development and functioning is 
coded on a nucleotide sequence, called DNA. The structural flexibility of the 
DNA allows its packing with structural proteins, e.g. histone proteins to higher 
order structures called chromatin (Lander, Linton et al. 2001). 
The human genome consists of 3 billion base pairs and encodes for 20,000 to 
25,000 genes. Of each gene a person owns two copies (alleles) – one inherited 
from each parent. The sequence varies for 0.2 % and such variations manly 
occur in non-coding regions. If the frequency of a specific genetic variant in a 
population reaches 1 % or more, it is referred to as a ‘polymorphism’. About 90 
% of all DNA polymorphisms occur as single base pair substitutions, called 
single nucleotide polymorphisms (SNPs) (Brookes 1999). The rest is due to 
restriction fragment polymorphisms, short tandem repeats, insertion-deletion 
variants, and other structural variants (Frazer, Murray et al. 2009). 
Polymorphisms can be functional (change amino acid code, alter expression or 
stability), or in linkage disequilibrium (LD) with functional variations. The LD 
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describes the non-random allocation of alleles at two or more loci to individual 
chromosomes as a result of recent mutation, genetic drift or selection. It is the 
difference between observed and expected allelic frequencies and measured as 
the variation of one SNP explained by the other (Hedrick and Kumar 2001). 
The “genotype” is the genetic constitution of each cell of an individual with 
reference to a specific trait under consideration. The “phenotype” is any 
observable trait of an individual. It is the visible and quantifiable effect of gene 
expression, environmental influence and the interaction between those two. 
Many different genotypes can result in one phenotype, or vice versa, many 
different phenotypes can be the result of one genotype. For example, obesity1 
phenotypes are anthropometric measurements like body mass index (BMI), 
waist circumference (WC), waist-to-hip ration (WHR), body fat content, skin fold 
thickness, or features like “higher weight gain” or “lower weight loss” (Rankinen, 
Zuberi et al. 2006). All this phenotypes are multifactorial traits each 
characterized by multiple genes and multiple environmental factors. Such a 
polygenetic background may involve major genes and a subset of genes with 
lower penetrance. The trait is caused by different genetic loci acting together, or 
a gene may be manifest only in the presence of a particular environmental 
exposure (Khoury, Little et al. 2004). 
Complex diseases are characterized by a heterogeneous etiology with different 
genetic backgrounds and environmental influences resulting in the same 
outcome. A profile describing a combination of risk factors is very unlikely to be 
found in more than one person.  
                                            
1 Obesity is a complex metabolic condition characterized by accumulation of lipids in 
body cells, markedly in adipocytes. 
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GENERAL EPIDEMIOLOGY 
The word epidemiology is based on the ancient Greek words “epi” meaning “on 
top of”, “demos” a root meaning “the people”, and “logos”, a suffix meaning “the 
study of”. Taken literally, the word refers to the study of what befalls people. 
One of the most commonly used definitions for epidemiology is “the study of the 
distribution and determinants of health-related states or events in populations, 
and the application of this study to control health problems” (Last, Spasoff et al. 
2001). 
History 
The Greek physician Hippocrates of Cos lived around 2,500 years ago and 
became the father of medicine and the first epidemiologist known. In his texts, 
he examined associations between environmental influences and the 
occurrence of disease. This idea of environmental contribution to the etiology of 
diseases may have been clouded by explanations with supernatural causes 
until the rediscovery in the 19th century. In the meanwhile several important key 
players helped shaping the discipline of epidemiology, as it is known today. 
Besides Hippocrates, some other pioneers in this area are worth mentioning. 
John Graunt (1620-1674) used systematic methods to describe diseases and 
calculate life expectancies, and Thomas Sydenham (1624-1689) was the first 
who used observational study approaches. In the 18th century, group 
comparisons and population thinking emerged when James Lind (1716-1794) 
observed the effect of time, place, weather, and diet on spreading diseases in 
the British army. Since then, epidemiologists have developed and refined 
concepts of research elucidating questions related to human health (Morabia 
2004). 
  
13 
 
 
Flow of research 
An epidemiologic theory gives opportunities to generate, test or screen for a 
hypothesis on a causal association between an exposure and a disease. 
Several approaches may be achieved such as, a descriptive (observational) or 
an analytical investigation. Furthermore, studies can be distinguished by the 
time of conduction (prospective/retrospective) (Rothman 2008). First steps 
when planning to conduct an epidemiologic study are definitions of aims and the 
nature of the outcome variable, and decisions on study design and methods of 
analysis. The probability of a study finding a true outcome depends on its prior 
probability (before doing the study) of being true, and its statistical power and 
significance (Pigeot 2007). 
Study designs 
For the purpose of this work, observational study designs will be the only 
designs discussed. Previous knowledge on causal relationships between 
environmental exposures and human diseases comes primarily from the two 
epidemiologic study designs: cohort and case-control study (Rothman 2008). 
The cohort study design often begins with a single group of persons 
heterogeneous to each other with respect to exposure history (source 
population). All participants are equal on developing the disease. They are 
followed over time and according to exposure status, divided into subgroups to 
ascertain disease occurrence (prospective). Cohorts can be defined from 
membership of administrative units, such as doctors or nurses, or defined from 
employment records, such as a cohort from mine workers.  
In a case-control study only a part of the population at disease risk is observed. 
Diseased cases arise from a source population. A control group with the same 
exposure distribution is chosen and the two groups are compared. The 
approach can be prospective as well as retrospective – depending on time of 
exposure recording the occurrence of disease. Cases and controls selected 
from a cohort make the study “nested” (Pigeot 2007; Rothman 2008). 
If case-control and cohort designs are population based, cases are 
representative of all cases in the population and controls are representative of 
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the source population of cases. The benefit of this approach it the interpretation 
of the outcomes for a whole population (Rothman 2008). 
Another commonly used observational study design on population level is the 
cross-sectional design. Without regard to exposure or disease status, a 
representative sample of the population is ascertained at a time. The different 
exposure subpopulations are compared with respect to their disease prevalence 
(Rothman 2008). 
Sample size strongly determines study power. The problem in planning study 
sizes is finding a balance between greater precision in results and greater 
costs. When planning a study, computational sample-size statistics serve as 
rough guidelines. These approaches relate study size to the design, study 
population, and to the desired power of precision, but do not account for 
anything that is not included as a variable in the formula (Rothman 2008). 
Data analysis 
After editing and summarizing the data, it is usually modeled in a 2x2 table 
(table 1) and analyzed for the estimation of the measurements of interest 
(discussed below). 
Table 1 The epidemiologic 2x2 table. Building subgroups stratifies the number in cells. 
Measurements are calculated as follows, absolute risk a/(a+b), RR a/(a+b) / c/(c+d), 
OR a/b / c/d. 
 Disease No Disease 
Exposed a b 
Not exposed c d 
Statistical testing of hypothesis focuses on the null hypothesis postulated as “no 
association between two variables”. In the alpha level of analysis the 
significance is approved usually based on a cutoff point (α, usually 5 %). The P-
value is the continuous measure of whether or not the hypothesis and data are 
compatible. If P > α, the hypothesis has to be rejected (Rothman 2008). The α-
error or type I error defines the probability of claiming a relationship when none 
truly exists. In the next level, the probability that a negative assumption is false 
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is tested (type II or β error). The probability of a study finding a true relationship 
reflects 1 – β. If the null hypothesis is rejected, the (more often very unspecific) 
alternative hypothesis is favored.  
The statistical estimation of measurements is another method to interpret data. 
A confidence interval (CI) is used to indicate the reliability of an estimate as 
100(1-α) %. If the model is correct and there is no bias, a CI will contain the true 
parameter with a frequency no less than its level (Rothman 2008). 
Modern epidemiology often relies on measurement estimations from regression 
analysis. Here, the focus is on the relationship between a dependent and one or 
more independent variables. Especially, when the data under analysis is limited, 
a Bayesian approach may be achieved. Such an analysis requires a prior 
probability distribution to combine with a likelihood function allowing the 
production of a new set of certainties for the parameter. 
Measures of occurrence, effect, and association 
The objectives of an epidemiologic study are measurements for valid and 
precise estimation of a disease frequency or the effect of an exposure on 
disease outcome. 
Ratios, risks, rates and odds that describe the occurrence of an event in the 
source population are the measurements computed from a 2x2 table (table 1). 
This measurements differ by the nature of their numerator and denominator and 
describe disease risk (absolute risk), association between exposure and 
disease risk (relative risk), or the impact of exposure-disease association 
(attributable risk) (Morabia 2004). The absolute risk is the probability to get 
diseased if exposed. The relative risk (RR) is the gold standard, eminently 
interpretable on the individual level as a given-fold increase in disease risk. 
What cannot be directly calculated from RR is the probability of being not 
diseased. An approximation of the RR is the odds ratio (OR). Only for very rare 
diseases the OR is the same as the RR. In contrast to the RR, the OR is 
symmetric so that the OR for the disease is the inverse of the OR for no 
disease. Furthermore, an OR based on exposure probabilities equals the OR 
based on disease probabilities. Impact measurements estimate the contribution 
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of an exposure to the incident rate1 at population level. The attributable risk is 
the most commonly used. In public health it is interpreted as a measure of the 
disease burden attributable, or at least related to one or several exposures 
(Pigeot 2007) 
Technically, all of the discussed measurements may be calculated from a 
cohort study. Case-control studies do only provide enough data for estimating 
RRs. Only if data is complemented by follow-up or population data (as for 
example in nested or population-based designs), an estimation of exposure-
specific rates is possible (Rothman 2008). 
Limitations 
The accuracy and reliability of estimates depends on unpredictable (random 
error) and predictable errors (systematic error) that may occur (Rothman 2008). 
In standard practice, each epidemiologic study is treated for the unpredictable 
sampling error that results from the assumption that each subject included in 
the study is a sample of people who could have been included in the study. 
Random error might also be due to fluctuations in the readings of a 
measurement apparatus (Porta, Greenland et al. 2008). An estimate with little 
random error is referred to as precise. Improving precision of a study will 
improve reproducibility of collected data and increase reliability. Random errors 
can be decreased by calculating means such as standard deviations, P-values, 
and CIs. The testing for hypothesis reduces the probability for random errors. 
Also, a common way to increase precision is to enlarge the sample size of the 
study (Rothman 2008). 
A systematical error (also referred to as bias) is typically constant, or 
proportional to the true value. An estimate with a little systematic error can be 
described as valid. Validity may refer to the source population (internal validity), 
or to the people outside that population (external validity or generalizability) 
(Porta, Greenland et al. 2008). 
                                            
1 Incidence rate is the number of new cases among subjects with a risk of disease 
development in the source population in a defined period of time.  
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Confounders are external factors associated with the disease and exposure of 
interest and are not intermediate steps in the exposure’s pathway to disease. 
Regardless of whether or not the exposure has an effect, confounding occurs if 
external factors become mixed with it. They can be eliminated or reduced later 
in data analysis (Pigeon 2007) (Rothman 2008). 
Selection bias occurs if control subjects were not representative of the study 
base from which the cases arose, or if not all the cases from the study base 
were identified. The distribution of environmental factors of interest among case 
patients and control subjects is not comparable due to the fact that the relation 
between exposure and disease is different (Pigeon 2007) (Rothman 2008). 
Information bias: errors in measuring information can occur throughout each 
phase of a study and may result in the substantial increase in sample size 
requirement for adequate statistical power. (Garcia-Closas, Rothman et al. 
1999) Measurements errors are for instance, questionnaire design and 
administration, biologic sample collection, processing and storage, sample 
labeling, through data coding, data entry, and analysis. For categorical factors, 
e.g. sex or body weight, an error in measurement is usually referred to as 
misclassification. Interaction of two or more factors can result in over or 
underestimation of the parameter. If a study relies on subject memory, time may 
affect recall and reporting, called ‘recall bias’ (Pigeon 2007) (Rothman 2008).  
An observational study is characterized by the examination of a population 
under a defined effect. The absence of randomization makes a causal inference 
largely speculative. At least, an epidemiologic study can only go to prove that 
an exposure could have caused (but not that it did cause) an effect in any 
particular case. Despite the main hypothesis, additional thoughts on sources of 
errors and bias are helpful and will be required. 
Addressing bias quantitatively in sensitivity analysis is an important process. 
Systematic errors might have larger effects than random errors, especially, in 
larger size studies. A lot of methods have been developed to adjust for 
confounders by standardization of rates and risks,or by stratification. The 
difficulty in bias analysis is the involvement of the analyst as they require many 
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choices and judgments from the investigators. Despite analytical tools, the 
Bradford Hill criteria (9 fundamental principles) are widely excepted and a 
helpful tool to provide adequate evidence of causality as well (Bradford Hill 
1965). 
Applications for findings 
Epidemiologic studies increase insights into biological processes. Data obtained 
is used for further investigations, and clinically relevant information is used in 
primary, secondary, and tertiary prevention and in clinical practice. 
Evidence based medicine (EBM) refers to clinical decision making based on the 
best available evidence about health care outcomes. Scales for evaluating the 
quality of evidence have been developed: Best evidence for evaluating medical 
interventions comes from well-designed randomized clinical trials. Best 
evidence for prevalence and risk assessment comes from large population-
based samples. And finally, best evidence for diagnostic accuracy of a test 
comes from studies comparing the test in representative affected and 
unaffected populations (Woolf, DiGuiseppi et al. 1996). Whether or not a 
biomarker achieved from research is valid for clinical use, has to be assessed 
individually. The ACCE model process (figure 1) for the evaluation of data was 
developed in 2000 by the Secretary’s Advisory committee on genetic testing but 
also applies to general epidemiology. The ACCE acronym represents the four 
main criteria: analytical validity, clinical validity, clinical utility, and 
ethical/legal/social issues.  
Analytical validity of a biomarker refers to its accuracy to measure what it is 
supposed to measure (analytical sensitivity1 and specificity2). The clinical 
validity includes its sensitivity and specificity in measuring a clinical or 
subclinical endpoint. The clinical utility refers to the risk for developing the 
disease with and without the use of the biomarker and accompanying 
interventions. 
                                            
1 Sensitivity is the probability that a test finds all positives. 
2 Specificity measures the proportion of negatives which are correctly identified. 
 Figure 1 Graphical representation of the ACCE model system. PPV, positive predictive 
value; NPV, negative predictive value (http://www.cdc.gov, 31
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Areas of concern 
Already in 1995 epidemiology has been occasionally viewed as having reached 
its limits (Taubes 1995). 
Common observational study designs are often incapable of answering the 
research questions which they are chosen for. Each approach has its 
advantages and problems. Many common diseases develop over long time 
periods making a follow-up expensive (Pigeot 2007; Porta, Greenland et al. 
2008). Furthermore, these study designs often have difficulties in locating 
people or their records many years after their enrollment into the study (Khoury, 
Little et al. 2004). For the diseases, the cohort design hardly gives sufficient 
power. In cross-sectional studies, cases with long duration are often 
overrepresented while those with short duration of illness are underrepresented. 
A big disadvantage of the case-control design is an overestimation of relative 
risks for common diseases (Pearson and Manolio 2008). Which design fits best 
depends on the research question, and the opportunities researcher have. 
The great flexibility in study designs, definitions, outcomes, and analytical 
modes makes them less likely to find true relationships (Ioannidis 2005). 
Furthermore, a lot of mistakes can be made with respect to study conduct, 
analysis and dissemination (Pigeot 2007). 
The statistical methods used in observational data analyzes have been 
developed for randomized trials. In randomized experiments, systematic errors 
are of little concern. In contrast, uncontrolled systematic variation in 
observational studies is the source of confounding factors and other sources of 
systematic errors. Most uncontrolled biases cannot be analyzed unless 
additional data for validation is available (which is usually not available or very 
limited). On the other hand, such validation studies may be subject to 
systematic errors themselves (Rothman 2008) 
The lack in replicating study results is a well recognized problem in the 
epidemiologic research community and can be caused by several factors. A 
research finding is less likely to be true the greater the financial and other 
21 
 
 
interests and prejudices. Replication rates drop further, the more research 
teams are involved in the same field (Ioannidis 2005). 
An obvious tendency of results being published when statistically positive or 
“interesting” entails a sort of “publication bias” that leads stakeholders to 
overemphasize results of individual studies (Rothman 2008). 
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HUMAN GENOME EPIDEMIOLOGY:  
GENETIC EPIDEMIOLOGY 
Flow of research 
Genetic epidemiology asks for the genetic contribution to a phenotype. Study 
designs are pedigree based. The flow of research starts with evidence for 
familial aggregation of a phenotype in nuclear families (index case and parents). 
If the pattern of correlation is consistent with a possible effect of genes, the 
mode of segregation is analyzed with e.g. affected relative pairs (sibs, cousins, 
or any two members of the family). Modes of inheritance for single gene 
disorders can be non-Mendelian (mitochondrial, imprinted) or Mendelian 
(autosomal recessive/dominat, X-linked) (Khoury, Little et al. 2004). 
If a clear mode of Mendelian inheritance can be described, the next step is a 
coarse mapping (> 1cM1) of the genome to narrow the region on the genome 
where the susceptibility locus is. Such a linkage study in related individuals 
(siblings or extended pedigrees) uses polymorphic markers for identifying 
biological mechanism for transmitting a trait or the approximate location of the 
involved gene. A linkage disequilibrium mapping is more precise about the 
location on the genome. The linkage approach has been proven to be very 
successful in identifying genes of large effect (e.g. cystic fibrosis). In common 
diseases with a complex background it is of limited success. The large size of 
the chromosomal regions shared among family members makes it difficult to 
narrow the linkage signal sufficiently in order to identify a causative gene 
(Pearson and Manolio 2008). 
A linkage analysis is a property of loci and requires family pedigrees; an 
association study deals with fine mapping (< 1cM) of alleles. Aim is the 
discovery of an association between an allelic variant and a trait, or to find LD 
between a susceptibility allele and a marker. Two approaches can be achieved. 
With an a-priori-knowledge, the candidate gene approach examines the role of 
                                            
1 Centimorgan, a unit of recombinant frequency for measuring genetic linkage. 
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a specific gene by associating it with a phenotype. For the last 15 years, 
candidate gene and genome-wide linkage studies have been the two main 
genetic epidemiological approaches to identify genetic loci for common traits. 
Since technical improvements allow for high throughput screenings with lower 
financial input, more and more articles report findings from genome wide 
association studies (GWAs) (Khoury, Bertram et al. 2009). Performing a whole 
genome screen in a Caucasian population requires 500,000 loci. As a 
consequence of LD, it is necessary to genotype only this subset of markers in 
order to capture common variation in the genome (Spencer, Su et al. 2009). 
This hypothesis-screening approach seeks for associations between genetic 
variants and phenotypes and does not require a-priori-knowledge (Manolio). 
GWAs detect common variants with low penetrance. Furthermore, GWAs are 
able to detect a gene-gene interaction, or a modification of an association by 
another variant (Pearson and Manolio 2008). 
The signal of a positive association is narrowed to potential causative variants 
in the haplotype block represented by the tag SNP (fine mapping). This 
determines whether one of the SNPs has a stronger association (than the tag 
SNP), or an established functional effect (Manolio). In the next step, a more 
valid study has to replicate the SNP to identify false positive findings. In such a 
multi-stage design, positive findings from a GWA (discovery set) are genotyped 
in an independent population sample (replication set 1). This yields to a smaller 
subset of significantly associated SNPs which are then tested in a third tier 
(replication set 2). The second replication is attempted in a study as similar as 
possible to the initial report. Later it is extended to related phenotypes, different 
populations, or different study designs (Chanock, Manolio et al. 2007). To 
detect variants with small effects, large consortia are often needed. Positive 
associations may also be investigated for their functional implications 
experimentally (Pearson and Manolio 2008). These processes help to minimize 
false positive associations. 
For the purpose of this work, an association study will be referred to as a study 
of any polymorphism across the entire human genome, designed to identify one 
or more associations with an observable phenotype. 
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Depending on whether the study population is family, or population based, 
several different designs, screening, and data analyzing methods may be 
achieved.  
Study designs in association studies  
Designs such as population-based case-control (most frequently used) and 
cohort designs do not differ in principle from general epidemiologic studies. 
Family-based designs are for example, sibling-controls in which affected 
individuals are cases and unaffected siblings are controls. Studying unrelated 
controls is more powerful to than studies using unaffected siblings as controls 
(Teng and Risch 1999; Li, Gail et al. 2002). A general problem of family-based 
association studies is the difficulty to apply to disease of middle or old age. 
Different reasons for availability of a sibling can be related to a great variety of 
factors such as social relationships, or socioeconomic and occupational status 
related to migration (Wacholder, Rothman et al. 2002). 
Unlike other markers of exposure, genetic variants can be seen as stable 
indicators of host susceptibility making the case-control approach particularly 
well suited. On the other hand, due to changes in environmental exposures over 
time, the cohort study design may be preferred. The nested case-control design 
merges both advantages, but is less cost intensive compared to a cohort study 
(Rothman 2008). Another opportunity to save costs is the case-cohort design 
(using a cohort as control group) (Khoury, Little et al. 2004). 
The cross-sectional design is used to estimate allele and genotype frequencies 
in populations. Further, relationships between frequencies and exposure levels 
or frequencies and phenotypes can be assessed. Although, cross-sectional 
studies may guide research and health policies, they are unable to identify 
incidence or causal inference. (Rothman 2008) 
Migrant, adoption, and twin study designs have been proven well in identifying 
any environmental contribution by identifying rapid changes that cannot be 
attributed to genetic factors (Khoury, Little et al. 2004). Case-control and cohort 
studies are the most often used designs to evaluate gene-environment 
interaction (Langholz, Rothman et al. 1999). 
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Statistical power in association studies 
A major criterion when detecting a causative variant is statistical power. It is 
determined by the effect size of the polymorphis, and the sample size of the 
study. Required sample sizes are normally calculated based on haplotypes in 
HapMap (http://hapmap.ncbi.nlm.nih.gov/). In the simulation modeling one has 
to think of a particular disease model and effect size, genotype frequencies in 
cases and the power of commercially available chips (Spencer, Su et al. 2009). 
Generally, the sample size tends to be very high according to allele frequency in 
the population, strength of association and further, to guarantee a low P-value. 
To detect interactions between common genetic polymorphisms and 
environmental exposures, required sample size is even larger (Manolio). 
Data modeling & analysis in association studies 
The 2x4 table is the tool of choice to evaluate if included factors are 
independent of each other (table 2).The role of each factor is assessed in terms 
of both, individual association and potential attributable fraction. ORs can be 
calculated for each possible combination (Rothman 2008) 
In the null hypothesis it is assumed that the vast majority of SNPs are not 
associated with the phenotype. Rejecting the null hypothesis of a locus implies 
that the SNP is associated. The analysis is based on the principles of LD, which 
means that the OR does not necessarily reflect the risk associated with the true 
mutation (it may be in LD with a causal SNP) 
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Table 2 Layout for a 2x4 table in a case-control association study to assess the effect 
of a genotype (G) and an environmental factor (E).  
G E Cases Control OR  Contrast Main Information 
+ + a b ah/bg A A vs. D Joint genotype and 
environmental factor 
vs. none 
+ - c d ch/dg B B vs. D genotype alone vs. 
none 
- + e f eh/fg C C vs. D Environmental factor 
alone vs. none 
- - g h 1 D  Common reference 
Other measures OR Main information 
Case-only OR ag/ce Departure from multiplicative model of 
interaction 
Control-only OR bh/df Independence of factors in population 
Multiplicative 
interaction 
A/(B*C) Deviation from multiplicative model of 
interaction 
Additive interaction A – (B + C – 1) Deviation from additive model of 
interaction 
Stratified 1-a ad/bc Association with environmental factor 
among people with genotype 
Stratified 1-b eh/fg Association with environmental factor 
among people without genotype 
Stratified 2-a af/be Association with genotype among 
people exposed to environmental factor 
Stratified 2-b ch/dg Association with genotype among 
people not exposed to environmental 
factor 
adapted from (Khoury, Little et al. 2004) 
Similar to general epidemiology, regression analyses is a core method in 
genome epidemiology. Data is modeled in additive or multiplicative ways to 
overcome numerical limitations of simpler methods. An extension of traditional 
regression analysis is the partitioning method (joint analysis of multiple genes 
for quantitative traits). It relies on genotypic partitioning based on multiple loci 
(Nelson, Kardia et al. 2001) 
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Limitations in association studies 
A successful genome screen is determined by the effect of the marker allele 
and the density of markers used (Pearson and Manolio 2008) (Chanock, 
Manolio et al. 2007). Additionally, adopted approaches and methods have their 
limitations as well. 
Study designs 
Pros and cons of common observational study designs have been discussed in 
previous chapters. Despite difficulties, case-control and cohort studies are best 
suited to evaluate common variants with small effects on complex traits. 
Sample size & study power 
To guarantee sufficient power, association studies require high sample sizes to 
be able to detect the modest effects of SNPs in a complex condition like 
(Manolio). Sample sizes are often limited by the number of well characterized 
clinical samples to include into the study population as examples of (Fogelholm, 
Valve et al. 1998), (Ukkola, Tremblay et al. 2001) and (Deeb and Brunzell 2009) 
demonstrate. Aside from that, sample size is often calculated based on HapMap 
chromosomes which results in oversampling those risk alleles (Spencer, Su et 
al. 2009).  
The 2x4 table is the epidemiologic tool most researchers used to work with. 
One can estimate the departure of the joint effect from specific models of 
interaction (e.g., additive or multiplicative) only by dichotomizing factors. With 
three factors, the exposure combinations become 8 (2³). With increasing 
complexity the number of possible combinations grows (2n for n factors) and 
corresponding tables rapidly become cumbrous (Khoury, Little et al. 2004). For 
example, the simultaneous testing of 5 genetic variants, with 3 genotypes each, 
gives 35 or 243 potential genotype combinations. Testing of 9 variants with 3 
genotypes each gives 19,683 combinations (Janssens 2008). Sample size 
requirements are an inescapable challenge (figure 2). 
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Figure 2 displays required case and control numbers to detect a 1.5-fold multiplicative 
interaction for varying prevalence values (P) of the “at risk” genotype (assuming a two-
sided test with 80 % power and an overall α-level of 5 %). The ORs are 1.0 for the at-
risk genetic variant in the absence of exposure, 2.0 for the exposure without the at-risk 
allele, and 3.0 for having both factors. Adapted from (Rothman, Wacholder et al. 2001) 
An increasing number of factors under study quickly reduce the per-stratum size 
within a fixed total number of subjects, and decreases study power. The more 
factors are involved, the less likely it is that interactions are described by simple 
multiplicative or additive models (Khoury, Little et al. 2004). Additionally, 
relations can be other than dichotomous, for example graded or continuous 
(dose-response) enhancing complexity. 
Modeling data 
As a matter of fact, the complexity of pathways often makes it difficult to 
examine the effects of exposures or genes at a time, without allowing for the 
influence of other factors also biasing the data (Khoury, Little et al. 2004). In the 
presence of unaccounted etiologic factors it will also be difficult to unravel 
interaction partners and joint effects (Pearson 2008). 
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Errors & bias 
Studies of human genome epidemiology hold new sources of errors and bias, 
additional to the problems that have been discussed in the general 
epidemiology chapter. 
Population stratification is a confounding bias by ethnicity and the most cited 
reason for inconsistency in results. Genotype distribution and disease vary 
across ethnic groups and correlate with each other. Estimations of allele effects 
on disease risk fail if heterogeneity in the study population is missed. But, even 
in the broad categories of ethnicity (e.g., Caucasians, Asians, etc) strong 
variations in allele frequencies may occur. If subgroups are identifiable (by 
genotyping or self-reported information) a standard technique such as statistical 
stratification deals with the problem (Rothman 2008; Khoury, Little et al. 2004). 
Another confounder is an unknown allele that is associated with the disease 
and in LD with the allele under study (Khoury, Little et al. 2004). 
Measurement error of genotype determinations is usually referred to as 
misclassification. This information bias can be reduces by including duplicate 
samples for quality control when performing genotype assays. By testing if the 
control population is in Hardy-Weinberg equilibrium1 can also help to identify 
such problems (Khoury, Little et al. 2004). Misclassification of case participants 
can markedly reduce study power and bias study results towards no 
association, particularly when large numbers of unaffected individuals are 
misclassified as affected (Pearson and Manolio 2008). Misclassification can also 
be due to LD, especially when the genotype is measured at DNA level 
(Rothman 2008). 
Genotyping errors result in spurious associations. They strongly decrease the 
ability to detect true findings.  
  
                                            
1 It is expected that in a population, genotype and allele proportions remain stable over 
generations. 
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Applications for findings, genetic testing 
Findings from GWAs enlarge the body of knowledge of biologic mechanisms in 
normal health and development and of disease causation (Pearson and Manolio 
2008). Their potential applications to improve health and prevent diseases 
should not be underestimated. They encourage the development of better drugs 
and tailor drug use to maximize benefits and to minimize harms. In response to 
several levels of exposure, genetic markers are stable indicators when 
measuring inter-individual variability. They are predictors of an individual's risk 
for developing a disease. 
A genetic test determines whether a person is a carrier of a mutation or not. In 
general, testing can be distinguished as followed: diagnostic testing (to confirm 
a diagnosis), predictive testing (presymptomatic testing for an individual’s 
susceptibility to a disease), carrier testing (test for presence of mutation), and 
identity testing (forensics). Furthermore, tests may predict optimal therapeutic 
regimens (the likelihood of response or toxicity). With respect to time, genetic 
tests are carried out prenatal, postnatal, and through the entire life.   
Today, for more than 2,160 diseases, genetic tests are available, 1,898 of them 
for clinical use (http://www.ncbi.nlm.nih.gov/sites/GeneTests/, 31th Aug 2010). 
A growing number of tests are looking at multiple genes that increase or 
decrease a person’s risk to develop complex diseases, such as several different 
types of cancers or diabetes. Altogether they have the potential to improve the 
health of individuals and entire populations. During this new era the ACCE 
model1 and 44 questions (directed at each of the preceding categories of the 
model) have been developed to evaluate data on emerging genetic tests.  
In the public health sector, the enhanced identification of subgroups based on 
genotypes will help to develop more effective interventions to prevent disease 
onset or progression (Caporaso and Goldstein 1995). 
  
                                            
1 Introduced on pages 18 and 19. 
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Areas of concern 
In the community of human genome epidemiologists, the lack of replicating 
study results is a well recognized problem. A meta-analysis included 370 
studies addressing 36 genetic associations for various diseases. It 
demonstrated that the first study often had suggested a stronger genetic effect 
than was found by subsequent studies (Ioannidis, Ntzani et al. 2001). A 
literature review of over 600 gene-disease associations by Hirschhorn et al 
revealed that most reported associations were not robust. Of the 166 
associations studied at least three times, only 6 were consistently replicated 
(Hirschhorn, Lohmueller et al. 2002). Additionally, a research finding is less 
likely to be true the more research teams are involved which might be due to 
the competition and publishing philosophies of editors (Ioannidis 2005). This 
lack of reproducibility has been varyingly attributed to some serious problems: 
In human genome association studies no stringent consensus exists on the 
study design fitting best a particular research question, the way to model and 
analyze data, and on what information to include in the report. Such flexibilities 
tend to reduce the probability of a research finding to be true (Ioannidis 2005).  
The methodological shortcomings of traditional study designs raise skepticism 
of the ability to identify and characterize genetic determinants of disease risk. 
The most widely used contemporary approach in the field is the population 
based case-control association study. It carries the most assumptions. If they 
are not met, substantial biases and spurious associations occur (Pearson and 
Manolio 2008). Another disadvantage is the difficulty of control group selection 
(Rothman 2008). In population based studies of this design, relative risks are 
overestimated quite often (Pearson and Manolio 2008). Cohort studies 
spanning over many years present logistic and financial problems adversely 
affecting validity. 
SNP associations identified in one population are often not transferable to other 
populations. If an environmental or genetic factor varies with ethnicity and with 
risk of disease, it acts as surrogate. In different populations diverse 
mechanisms can contribute to the same phenotypes. Furthermore, variations in 
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allele frequency defined by ethnicity or geographic origin falsely identify 
subgroup-associated genes related to disease (Pearson and Manolio 2008). 
In data analysis, correcting for multiple testing assumes independent 
associations of each SNP which is simply false because individual SNPs 
correlate to some degree due to LD (Pearson and Manolio 2008).  
The large number of possible allele combinations and non-genetic risk factors 
result in high rates of false positives (Khoury, Little et al. 2004) (Yang, Kelly et 
al. 2007). Association studies often carry limited and biased information on 
environmental exposures or other non-genetic risk factors (for example, 
inquiring ethnicity or food frequencies1). Stratifying data on such information 
results in the problem of sparse data. 
Emerging technologies allow the simultaneous measuring of hundreds and 
thousands of SNPs, gene expression profiles, and protein patterns. A large 
amount of data on each individual is the rule rather than the exception. The 
emerging complexity in data analyses, especially in complex networks, raises 
concerns. 2x4 tables, stratified analyses, and logistic regression analysis are 
already facing limitations (Rothman 2008). For instance, regression modeling is 
limited in the number of variables that it examines simultaneously. The results 
of Nelson et al suggest that traditional methods of building multiloci models 
simply fail to identify combinations that best predict a trait’s variability (Nelson, 
Kardia et al. 2001).  
Although, estimation of effects should be favored, researchers use probabilities 
of data as measures of compatibility between data and hypotheses, or as 
measures of the relative support that data provide hypotheses (Rothman 2008). 
Statistical methods for analyzing data from observational studies were 
developed for randomized trials. In randomized experiments, systematic errors 
                                            
1 Self-reported ethnicity is a better surrogate for environmental risk factors than 
genome-based methods (people’s behavior is likely to be closer to the ethnicity they 
identified themselves with, than to the ethnic composition of their genome) (Wacholder 
Rothman, et al 2002). 
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are of little concern. In observational studies, the uncontrolled systematic 
variation is the source of confounding factors and other sources of systematic 
errors. Most uncontrolled biases cannot be analyzed unless additional data for 
validation is available (which is usually not available or very limited). 
Furthermore, such validation studies may be subject to systematic errors 
themselves (Rothman 2008). 
Association studies generally rely on the LD. After several generations, genetic 
recombination leads to complete independence between a marker allele and a 
disease allele in the same region. This fact is accelerated by population 
admixture, genetic drift, rate of mutation, non-random mating, selection, and 
genetic linkage (Vogel 1996). The use of marker alleles in case-control studies 
leads to misclassification and a dilution of the OR (Rothman 2008). 
Many features in design and analysis of GWAs aim the minimization of type I 
error while maintaining the power to identify true-positive associations. Such 
efforts could be demonstrated to result in overlooking a true association. In a 
multi-stage design, the most robust findings often are not the most statistically 
significant associations in the initial scan (Pearson and Manolio 2008). The 
diligent search and correction for biases is important as they are able to reduce 
the magnitude of an observed association towards null. 
Genotyping a population of European ancestors with a commercial platform of 
500,000 markers (recommended marker density) fails to capture structural and 
rare variants, and relatively young mutations (Pearson and Manolio 2008). If a 
true causative SNP is not captured, several markers on the chip correlating with 
it may give a signal of significant association and hence allow detection of the 
locus. The complexity of a LD does not allow analytically capturing of this effect 
so that it has to be accessed via simulation studies (Spencer, Su et al. 2009). 
These problems can lead to a missing bulk of the heritable fraction of in 
complex traits.  
High rates of false positive results are also due to multiple statistical testing on 
the one side and a large number of possible allele combinations in a complex 
trait on the other side (Khoury, Little et al. 2004) (Yang, Kelly et al. 2007). The 
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large-scale data mining with overestimation of statistical significance testing 
leads to numerous positive associations that are not replicated (Rothman 2008). 
Genome association studies provide little information on the functional basis 
and the link between genetic polymorphism and a complex trait (Pearson and 
Manolio 2008). 
Genetic testing 
An increasing development of commercial platforms selling genome-wide 
association-based screenings directly to the consumer can be recognized. In 
the beginning, most of the tests (were designed and thus) applied only for 
families with a strong history of a specific disease. However, in recent years, the 
growing list of susceptible genes made tests available for everyone interested. 
Today, many companies offer clinically available tests for a range of disorders 
and diseases, and/or extend to genetic tests for nutrition, behavior and aging. 
However, resulting reports often include information based on inadequate 
evidence. Predictions are based on average risks which are difficult to apply to 
an individual person. Nevertheless companies already give advice on how the 
risk for these diseases can be reduced using medical, behavioral, and 
environmental interventions (Khoury, Little et al. 2004) (Manolio). A study of the 
Government Accountability Office for example, investigated results of direct-to-
consumer test results. 14 hypothetical consumer profiles, generated from only 
two sources, were sent to four different web sites offering genetic tests. The 
report concluded that the information passed on to consumers was "misleading" 
with respect to the terminology and the inconsistency of disease prediction for 
identical samples. Furthermore, the recommended, “personalized”, nutritional 
supplements offered by some of the companies were in fact not customized 
(http://www.genome.gov/19518344). 
The little information on analytical validity of many tests makes it difficult to 
decide whether different studies of the same genetic trait used comparable 
laboratory methods (Burke, Atkins et al. 2002). For the accuracy of the 
prediction, quality of samples and medical history collected from family 
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members are as important as the technical aspects of the testing process in the 
laboratory. 
SNPs uncovered by GWA analysis are noisy measurements of the genotype at 
the position of the causal variant and the risk associated with its occurrence is 
unclear. Nevertheless, evidence from GWAs is often used to predict diseases. 
Other genetic tests are developed from studies observing variations associated 
with disease susceptibility in multiple affected family members. Such high-risk 
families represent the severe end of a spectrum of risks associated with 
mutations and tempt to overestimate the risk by not integrating other factors that 
may modify risk (Burke, Atkins et al. 2002). 
Another problem of available tests is that they are merely not ‘yes or no’ 
decisions and rather predict relative risks (giving a probability for developing the 
disease) (Khoury, Little et al. 2004) In other words: people carrying a 
polymorphism associated with a complex disease not necessarily develop the 
disease.  
Currently, a huge amount of causal variants has not been identified and it is 
impossible to assay all known human genome variations. The consumer may 
still carry a susceptibility variant and develop the disease even if the test tells 
him he is not. Commercially available genotyping chips further limit the 
variations tested. Furthermore, the risk of disease will only marginally differ 
between carriers and non-carriers of risk variants of one single susceptibility 
gene (Janssens and van Duijn, 2008). The complex interactions also influence 
and result in differences in clinical validity. 
Even if a risk factor is well established, the clinical utility might still be low. For 
many of the diseases which can be tested, no effective preventive or 
therapeutic treatment exists yet. Genetic variance alone probably cannot 
account for disease susceptibility without the addition of pre- and postnatal 
environmental and/or behavioral factors. Moreover, an interaction between 
genetic and environmental factors has to be accounted for, e.g., in genomewide 
association studies. Advanced and new tools are needed for unraveling 
complex diseases.  
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MOLECULAR EPIDEMIOLOGY 
Molecular epidemiology deals with genetic and environmental factors 
contributing to diseases on the molecular level. It entails the inclusion of 
molecular measurements in epidemiologic research. Molecular techniques are 
used to measure exposure, biologic responses, or host characteristics 
influencing susceptibility to adverse health outcomes. The aim is not to 
formulate new etiologic hypotheses but to reveal mechanisms and events that 
occur along the theoretical continuum between exposure and the associated 
disease. It offers higher resolution answers in relation to disease causation 
(McMichael 1994) (Vineis and Perera 2007). 
Biomarkers 
Molecular biomarkers have first been applied in cancer epidemiologic research 
in the 1980s (Perera and Weinstein 1982). They can be categorized as markers 
of internal dose, markers of biologically effective dose, markers of early 
response/effect, markers of susceptibility, and markers of altered structure and 
function (1987). 
Epigenetics investigates heritable changes in gene expression that alter 
chromatin without changing the DNA sequence. The Epigenome is the overall 
epigenetic state of a cell including all mechanisms and marks such as non-
coding RNAs, the histone code, and DNA methylation (Holliday 2006). The 
epigenotype is tissue and cell-type specific and varies over time as a function of 
time, environmental factors, and random processes (Foley, Craig et al. 2009). In 
the germline, during embryogenesis, and the first years of life the epigenome 
undergoes reorganization. Cued by surrounding environments, it results in the 
sensitization for later environmental factors – a so called “programming of the 
genotype” (Hales and Barker 2001). A number of studies demonstrated that 
nutritional components and lifestyle factors (Misík 2010; Rust 2010; Stefanska 
2010; Thaler 2010), toxins (Bursch 2010) and endocrine disruptors (Sato, 
Fukata et al. 2006), radiation (Schofield 1998), air pollution (Bursch 2010), and 
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maternal behavior (Szyf, Weaver et al. 2007) influence the epigenetic state of 
cells dynamically during the entire life. With age, a general decrease in 
tissue/gene specific DNA methylation1 has been reported and genome-wide 
and specific methylation patterns could be identified (Foley, Craig et al. 2009; 
Komninou 2010). This developmental plasticity makes it possible to develop a 
range of phenotypes from a single genotype. Epigenetic modifications can be 
stably passed over numerous cycles of cell division and some alterations can 
even be inherited from one generation to the next (Kaati 2010). They have been 
suggested to form an alternative, “soft inheritance” system (Jablonka and Raz 
2009). 
Disruption of the epigenetic profile raises the probability of dysfunctioning of 
gene activity control and nuclear architecture with severe consequences for 
health (Esteller 2008) (Espada and Esteller). Epigenetic research had its 
breakthrough in cancer research where the difference in tumor suppressor gene 
methylation between cancerous and noncancerous tissue are sometimes close 
to 100%. Specific methylation profiles have also been associated with predicting 
factors of prognosis (Esteller 2008; Bursch 2010; Komninou 2010). 
The epigenome is already a field of research in several other complex diseases 
as for example, neurodegenerative disorders (Migliore 2010), asthma (Miller 
2010), viral infections (Huber 2010) and the metabolic condition obesity 
(Campion, Milagro et al. 2009). 
In this work the following types of epigenetic markers will be discussed: 
− DNA methylation: is a dynamic marker of the transcriptionally repressed 
gene (Bird 2002). Methylation is measured at specific sites, or as the 
overall level of methylation pattern in a tissue (Foley, Craig et al. 2009). 
− Histone modifications: Depending on type, amount, site of modification 
and its reversibility the modification results in different transcriptional 
outcomes (table 3) (He and Lehming 2003). 
  
                                            
1 the covalent addition of a methyl group to a cytosine that precedes a guanosine in the 
DNA sequence (the CpG dinucleotide) 
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Table 3 Examples of histone modification and their transcriptional outcome.  
 monomethylation dimethylation trimethylation acetylation 
H3K4 Activation 
(Bernstein, 
Humphrey et al. 
2002) 
 Activation 
(Koch, Andrews 
et al. 2007) 
 
H3K9 Activation 
(Lachner, 
O'Carroll et al. 
2001) 
Repression 
(Rosenfeld, 
Wang et al. 
2009) 
Repression 
(Barski, 
Cuddapah et al. 
2007) 
Activation 
(Kurdistani, 
Tavazoie et 
al. 2004) 
H3K27 Activation 
(Lachner, 
O'Carroll et al. 
2001) 
Repression 
(Rosenfeld, 
Wang et al. 
2009) 
Repression 
(Barski, 
Cuddapah et al. 
2007) 
 
H4K20 Activation 
(Margueron, 
Trojer et al. 2005) 
   
Validation of biomarkers 
Biomarkers are validated for their ability to predict for preventive or clinical 
purposes and, in intervention studies, reflect the modification of the natural 
course of disease (Vineis and Perera 2007). Technical validation deals with 
intrinsic measurement error and analytic sensitivity, for example, the ability to 
detect exposures at levels that exist in real human populations (Albertini, 
Nicklas et al. 1996). Epidemiologic validation is about the marker’s behavior in 
the population, depending on variability within the population, for example, 
variability between subjects (inter-individual) or within subjects (intra-individual). 
In order to identify intergroup differences (e.g., exposed vs. unexposed, healthy 
vs. diseased), the total intragroup variation needs to be minimized. (Vineis and 
Perera 2007). 
39 
 
 
The validation process is three major steps starting from the development of the 
biomarker, to its characterization, and to the final step of longitudinal1 studies. 
The gold standard of study design is cohort studies, but also nested case-
control and case-cohort designs are common (Bonassi and Au 2002). 
Techniques 
Molecular epidemiologic research is equipped with the standard epidemiologic 
tools and methods that have been discussed in previous chapters. Biomarkers 
measure factors, outcomes, confounders or effect modifiers. To be able to 
adjust for the intragroup variation several strategies are pursued. The collection 
of repeat samples, documentation on information on subject characteristics 
influencing intersubject variation, documentation on information on conditions 
under which samples have been collected and laboratory analyses are common 
methods (Vineis and Perera 2007).  
Limitations 
Studies are subject to similar problems and pitfalls as general epidemiologic 
studies. With the addition of biomarkers, pertinent issues that have to be 
considered are for example, analytic batch effects, storage effects, and freeze-
thaw cycles. They can create random noise or bias with the same 
consequences as misclassification of exposure in epidemiologic studies and 
have an impact on study validity (Rundle, Vineis et al. 2005). 
Areas of concern 
Already discussed in the chapter about general epidemiology, concerns regard 
the limitations of study designs, required sample sizes, statistical analysis, and 
the reporting and interpretation of results as discussed in previous chapters. 
The availability of validated biomarkers is still limited. Although in use, most 
available biomarkers require further validation. Main concerns are, the 
relevance to the exposure of interest, its specificity and sensitivity (Boffetta). 
                                            
1 A longitudinal study involves repeated observations of the same trait over long 
periods of time, mostly decades. 
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An enormous amount of studies even fails to use validated biomarkers. The 
complexity of a study increases enormously when integrating multiple markers, 
each reflecting a different stage or mechanism in the etiology (Perera and 
Weinstein 2000). 
New markers introduce increased potential for bias and confounding (Vineis 
and Perera 2007). For instance, the quality of the biomarker data might not be 
comparable in the case series and the reference group (Rundle, Vineis et al. 
2005). Further, timing issues such as when the laboratory begins the analytic 
runs of the samples, or the life course of the underlying cohort influence 
batching decisions, differences in storage duration between subgroups, and the 
likelihood that sample aliquots will have endured freeze-thaw cycles (Rundle, 
Vineis et al. 2005). Most biomarker-based studies of both, prospective and 
retrospective design rely on a single biological sample (Boffetta). 
Applications for biomarkers 
In cross-sectional, retrospective, prospective and nested case-control 
epidemiologic studies biomarkers offer new opportunities to overcome 
limitations of general epidemiologic methods as demonstrated in cancer 
research (Hemminki K. 1997; Hagmar 2005). 
In epidemiologic studies, once biomarkers are validated, they can be used to 
assess exposure more validly and precisely than exposure information is 
gathered via questionnaire and historical information such as employment 
records and monitoring data. Markers can show biological plausibility for an 
exposure proposed as etiologically relevant (Vineis and Perera 2007). Newer 
biomarkers can be combined with the more traditional biomarkers in hypothesis-
testing studies (Bonassi and Au 2002). 
Once biomarkers are validated properly, they are also used for clinical purposes 
like early diagnosis, prognosis, and follow-up and to predict potential risks for a 
group or population more precisely and to introduce better interventions (Perera 
and Weinstein 1982) (Perera and Weinstein 2000) (Vineis and Perera 2007). 
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CASE STUDY: ADAPTIVE THERMOGENESIS IN OBESITY 
The potential of results coming from genome association studies to predict the 
risk of complex diseases has been anticipated since the first publication, but this 
application is problematic. Currently known variants explain only little of the 
heritability of diseases. The resulting lack in replicating results leads to 
skepticism all over the research community. Unraveling the complex multi-gene-
environment interactions responsible for most diseases of public health 
importance seems to be more challenging than expected (Manolio). 
Obesity is a common complex condition. It is a major risk factor for common 
chronic diseases such as diabetes, diseases of the cardiovascular and 
musculoskeletal system, and some cancers (Haslam and James 2005). The 
World Health Organization (WHO) defines overweight as body mass index 
(BMI) 25 – 30 kg/m2 and obesity ≥ 30 kg/m2. Once considered a problem only in 
high-income countries, overweight and obesity are now dramatically on the rise 
in low- and middle-income countries, particularly in urban settings. WHO 
projects that by 2015, approximately 2.3 billion adults will be overweight and 
more than 700 million will be obese. 
Obesity is a highly heritable trait with estimates ranging from 50 – 70 % for BMI 
(Allison 1996) and from 75 – 80% for total body fat (Stunkard 1986). In 2006 the 
last update of the Obesity Gene Map Database summarized positive 
associations for DNA sequence variation with obesity phenotypes in 127 
candidate genes. Among them are (those showing replications in at least 10 
studies): PPARG (30 studies), ADRB3 (29), ADRB2 (20), LEPR (16), GNB3 
(14), UCP3 (12), ADIPOQ (11), LEP (11), UCP2 (11), HTR2C (10), NR3C1 
(10), and UCP1 (10) (Rankinen, Zuberi et al. 2006). Since then, many more loci 
have been identified, but they still account for little of the heritability, often less 
than 1 %. Yet, the scientific community is a long way from reaching a 
comprehensive picture of the heritable components of obesity and advancing 
from plain statistical significance into a biological understanding where the true 
contribution to a trait is recognized. 
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Body fat content, energy expenditure & obesity 
The human body harvests energy as fat in adipocytes as a reserve in 
undersupplied times. The regulation of body fat content results from an 
integrative network influenced by the central nervous system, the 
gastrointestinal tract, the adipocytes itself, skeletal muscles, taste receptors and 
by multiple nutrient, drug, toxin, sensory, and hormonal inputs. Furthermore, 
circadian rhythm and physical, gut and social environments influence the 
network. 
Adipocytes can be found in tissues mixed with other cells and in stereotypic 
depots all throughout the body and can be defined by function, brown or white 
adipocytes. Brown adipose tissue (BAT) serves as thermogenic organ by 
dissipating energy while white adipose tissue (WAT) has the contrary 
physiological function: energy storage (Rosen and Spiegelman 2006). Brown 
adipocytes contain multiple small droplets of triglycerides and a high number of 
mitochondria giving them the ability to oxidize high amounts of fatty acids (Silva 
2006). Mature white adipocytes exclusively transcribe the full machinery of 
enzymes and regulatory proteins needed to carry out lipolysis and de novo 
lipogenesis (Kopelman 2000). In mice, the occurrence of cold induced brown 
adipocytes in WAT is well established (Cousin 1992; Guerra 1998). Recently it 
could be demonstrated to be due to a transdifferentiation from adult white to 
brown adipocytes with similar morphology (Barbatelli, Murano et al.). 
The mechanisms underlying differentiation from a multipotent mesenchymal 
stem cell to a preadipocyte and a mature adipocyte are not fully understood yet, 
Although, the orphan nuclear receptor peroxisome proliferator activator receptor 
gamma (PPARγ) and the transcription factor CCAAT/enhancer-binding protein 
alpha (CEBPα) have been demonstrated to be essential (reviewed in Rosen 
and Spiegelman 2006). 
 
Accumulation of WAT results in excessive weight gain and is a major risk factor 
for chronic diseases such as: cardiovascular disease (mainly heart disease and 
stroke), diabetes, musculoskeletal system disorders and some cancers 
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(endometrial, breast, and colon) (Haslam and James 2005). Energy expenditure 
is the crucial factor to main energy balance and a healthy weight. The skeletal 
muscle and its aerobic oxidation of glucose and fatty acids is the dominant 
mechanism for dissipating energy. Adaptive thermogenesis in BAT protects the 
body from hypothermia and is responsible for 1 – 2 % of the overall energy 
expenditure, preventing a weight gain of 1 – 2 kg/year (Gesta 2007). 
Core elements in adaptive thermogenesis in BAT thermogenesis 
In BAT mitochondria, uncoupling of oxidative phosphorylation from ATP 
synthesis by the uncoupling protein 1 (UCP1) enhances heat production (Silva 
2006). Participating factors and interaction partner in the network of the UCP1 
transcription activation are displayed in figure 2. The UCP1 gene holds (among 
other regulatory elements) a response element for the nuclear receptor family of 
PPARs. PPARγ is a member of this transcription factor family and acts as 
sensor for a variety of lipids and lipid like compounds (e.g. ω-3 fatty acids). 
Different promoters in the gene and alternative splicing result in several 
isoforms. For instance, PPARγ2 is expressed exclusively in adipose tissue 
while PPARγ1 can also be found in liver and other tissues (McClelland, 
Shrivastava et al. 2009). Ligand binding to the receptor initiates the gene 
transcription process through conformational changes, a heterodimerization 
with the retinoid acid X receptor alpha (RXRα) and the assembly with 
coactivators to a multiprotein complex (Kliewer, Umesono et al. 1992). PGC1α 
acts as a ligand-independent coactivator for PPARs and is expressed 
preferentially in BAT. Histone acetylase (HAT) activity of coactivators leads to a 
modification of the chromatin structure of the proximate DNA allowing the 
complex to bind to a respond element and to initiate transcription. In the 
absence of ligands, a PPAR interacts with corepressor proteins and builds a 
complex with histone deacetylases (HDACs) which results in a locally more 
compact chromatin packaging (Li, Pascual et al. 2000). The binding of the 
PPARγ2/RXRα/PGC1α complex to the respond element of UCP1, followed by 
its transcriptional activation, have been demonstrated to be essential in brown 
adipogenesis (Barak, Nelson et al. 1999). Other PPARγ target genes are, for 
example, the extracellular lipoprotein lipase (LPL) which mediates the uptake of 
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fatty acids into the cell (Wang and Eckel 2009), and the fatty acid binding 
protein 4 (FABP4) which is expressed exclusively in adipocytes and 
macrophages. Although the role of the fatty acid carrier protein FABP4 is not 
well understood, its function could be correlated to lipid metabolism (Shin, Li et 
al. 2009). LPL is also a target gene of CEBPα who is also a transcription factor 
for the beta-3 adrenergic receptor gene (ADRB3) (Rosen and Spiegelman 
2006). For rapid adjustment the ADRB3 in BAT is targeted by catecholamines in 
response to cold (Silva, 2006). The activation of the receptor signaling results in 
an increased expression of the PGC1α gene (Cao, Daniel et al. 2004). 
The capacity of the described network strongly depends on environmental 
influences. Fatty acids are the only substrate for oxidative phosphorylation in 
BAT and also act as ligands of the nuclear receptor PPARγ. RXRα is a high 
affinity nuclear receptor for 9-cis retinoic acid, a metabolite of retinoic acid. 
Increased uncoupling of the respiratory chain from ATP production depends on 
the activation of the ADRB3 in response to cold (Silva 2006). Generally, the 
thermogenic activity of BAT depends on the degree of stimulation by the 
sympathetic nervous system, the amount of UCP1, and available substrate. 
(Trayhurn, Jones et al. 1982)  
 
Less activity of UCP1 results in a more efficient energy coupling and lower 
metabolic rates, both predictors of weight gain (Cypess and Kahn) UCP1 
deficient mice are cold intolerant, but surprisingly not ob. When fed with a high-
fat diet, they gain less weight than wild type (WT) controls. This Ob resistance is 
ambient temperature dependent because when mice reared at room 
temperature deficient mice gain weight faster than WT (Silva 2006). In obese 
humans a reduced expression of UCP1 mRNA down to 50 % was 
demonstrated (Oberkofler 1997). It is speculated that mutations reducing the 
activity of the protein diminish energy expenditure (Dalgaard 2001). 
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Figure 3 Participating factors and interaction partner in the network of the UCP1 
transcription activation.  
Nowadays, consumers can already test their risk for developing obesity by 
companies like 23andMe1. They for example, predict by testing for the SNP 
rs3751812 in the FTO gene. Markers in the area of this gene appear to be 
associated with BMI and carriers of the variant weight about 3 kg more. 
Although, it is not known yet how the gene affects BMI. Furthermore, it has only 
been replicated in Caucasians (Frayling 2007). 23andMe tests two other, even 
more speculative, variants (rs7566605 and rs6232). Each of these SNPs have 
been related to obesity of Caucasians in one study only. The first study could be 
replicated once, while four studies disputed the result. The other SNP (rs6232) 
has even only associated once.   
                                            
1 www.23andme.com  
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OBJECTIVES 
Issue of this work is the integration of epigenetic markers in human genome 
epidemiologic studies.  
In a case study of an important network in adaptive thermogenesis and obesity 
the synergisms of genetic and epigenetic regulation will be demonstrated. This 
will highlight the need for a systematic concept that integrates different types of 
biomarkers into epidemiologic research.  
The benefits for public health specialists and clinicians with special focus on 
genetic testing shall be discussed. 
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METHODS 
A systematic literature focused on most frequently observed SNPs and 
evidence for epigenetic regulation in genes of adaptive thermogenesis (table 3). 
The literature search revealed observational studies associating the 
polymorphisms with anthropometric measurements and other related ob 
phenotypes (English language). Studies were included that reported positive 
and negative associations in Caucasians and mixed ethnicities, by not 
distinguishing between self-reported and genome based methods to evaluate 
ethnicity. If no ethnicity was reported, a study was included if conducted in 
central Europe, and if it could be assumed to include Caucasians. Evidence for 
epigenetic regulation of the same genes was searched in PubMed by using the 
terms “gene” and/or “gene name” and “epigenetic” and/or “methylation” in title 
and/or abstract. Additionally, reference lists from articles were searched for 
further suitable studies. English publications giving sufficient information on 
DNA methylation and histone modifications in the genes were summarized. No 
other variations (e.g. frame shift mutations or copy number variations) than 
selected SNPs and no other data on posttranscriptional modification than 
epigenetic modifications are included. 
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Table 4 List of genes under observation. 
Gene name Gene Gene map 
locus 
SNP 
Uncoupling protein 1 UCP1 4q31 A-3826G 
Retinoid acid X receptor alpha RXRα 9q34 - 
Peroxisome proliferated activator 
receptor gamma coactivator 1 alpha 
PGC1α 4p15 rs8192678 
Peroxisome proliferated activator 
receptor gamma 
PPARγ 3p25 rs1801282 
Lipoprotein lipase LPL 8p22 rs285 
rs320 
rs328 
Fatty acid binding protein 4 FATBP4 8q21 rs1054135 
CCAAT/enhancer-binding protein 
alpha 
CEBPα 19q13 rs12691 
rs41490344 
rs41504144 
rs41344151 
rs16967952 
rs34508287 
rs41428545 
rs34529039 
rs41367646 
rs1049969 
rs707656 
Beta-3 adrenergic receptor ADRB3 8p12-p11 rs4994 
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RESULTS 
Results are summarized in tables R1 – R18 on page 54 – 67. 
PPARγ 
Genetic polymorphisms: The Pro12Ala (rs1801282) is one of the most 
prominent SNPs in the PPARγ gene. It has been observed for associations with 
phenotypes of the metabolic syndrome for many years. The literature research 
revealed a meta-analysis that included over 19,600 subjects and positively 
associated the Ala variant with increased BMI (table R1).  
Epigenetic modifications: In the past, six studies observed DNA methylation, 
and eleven studies observed histone modifications of PPARγ. In adipocytes, the 
correct epigenetic modification of the promoter region seems to be essential 
during cell differentiation and for the maintenance of the adult state of the cell. 
In tables R2 and R3, studies observing epigenetic regulations are summarized. 
In cells from a human umbilical cord where PPARγ2 is not expressed, its 
promoter region is hypermethylated. In human gastric mucosa cells of ulcer and 
cancer patients, hypomethylation of the promoter region was observed which 
concurs with findings from cancer research where cancerous cells become 
globally hypomethylated and tumorsuppressor genes hypermethylated (Esteller 
2008). In human adipose stem cells, the promoter region is hypermethylated 
and gradually demethylated upon induction of differentiation in 3T3-L1 cultures. 
Furthermore, promoter methylation in lean mice was increased compared to ob 
mice. Studies on histone modifications unravel a similar picture. Several 
independent research groups replicated the enzymatically coordinated 
deacetylation and methylation events at specific sites of H3 and H4 facilitating 
the transcription of the gene during adipogenesis (R3). 
RXRα 
The search for RXRα, the heterodimerization partner of PPARγ, has not 
revealed much literature.  
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Genetic polymorphisms: When screening the gene for DNA variants, Hegele et 
al (Hegele and Cao 2001) identified 3 common variations in Caucasians: -25 
A>G, 69 G>A, and 1470 C>T. Though, the receptor has an important role in 
development and metabolism, no study associated any genetic variation with 
obesity traits.  
Epigenetic modifications: The search for evidence on epigenetic regulation in 
the gene revealed one study examining the effects of green tea on 
demethylation of the promoter region in cancerous mice (Volate, Muga et al. 
2009). 
C/EBPα 
Genetic polymorphisms: The gene encoding for C/EBPα holds several 
polymorphisms that have been associated with different types of cancers. Two 
groups have studied their contribution to obesity (table R4).  
Epigenetic modifications: Eleven studies reported on evidence for DNA 
methylation and six studies on histone modifications (tables R5 and R6). 
Heterogeneous responses to inhibitors of histone and DNA modifying enzymes 
demonstrate both mechanisms beeing involved in the transcriptional regulation 
of the gene. C/EBPα is incapable of a direct interaction with DNA-Mtase1 
(Hervouet, Vallette et al. 2009) but several studies demonstrated that a 
C/EBPα-HDAC complex is able to silence several protein coding genes due to 
aging (Jin, Wang et al. 2009).  
ADRB3 
Genetic polymorphisms: Studies observing associations of the SNP Trp64Arg 
(rs4994) with obesity are summarized in tables R7 and R8. The last meta-
analysis, published in 2008, included 53 studies in Caucasians and had an 
overall size of about 23,000 individuals. No positive association/s could be 
detected. Since then, ten more studies had been published associating the SNP 
with obesity traits (table R8). Seven studies with an overall all size of 8,323 
subjects did not detect an effect, while 4 studies (1,267 subjects) each did 
detect positive associations.  
                                            
1 DNA methyltransferases are enzymes transferring a methylgroup to CpGs. 
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Epigenetic modifications: Searching for epigenetic evidence of the ADRB3 gene 
itself did not reveal any studies. However, the stimulation of the receptor 
induces the expression and recruitment of a demethylase to the promoter of the 
UCP1 gene and facilitates the ability of PPARy, RXRα and their co-activators to 
bind to the response element on the DNA.  
UCP1 
Genetic polymorphisms: Groups observing genetic variation in the UCP1 gene 
merely focused on the A-3826G substitution which was associated in fifteen 
different studies (table R9). A gender specific effect observed by two groups 
(total 701 women) could not be replicated by two other groups (total 77 women). 
Furthermore, a study including 722 men did not detect any effect. Eleven 
studies with an overall size of 4,466 subjects could not positively associate the 
polymorphism with obesity, even though 3 studies (all together 557 subjects) 
did.  
Epigenetic modifications: Two observations of the promoter region on DNA 
methylation and three on histone modifications (table R10) in several different 
tissues revealed tissue specificity. In 3T3-L1 cultures gene, silencing by DNA 
methylation and repressive histone modifications have been demonstrated by 
different groups. 
PGC1α 
Genetic polymorphisms: The coactivator PGC1α holds the SNP rs8192678 
which changes the amino acid sequence at position 482 from glycin to serin. It 
is the most examined polymorphism in the gene in relation to obesity. The 
thirteen studies revealed by literature are summarized in table R11. No effect of 
the variant was detected by studies (all together 16,000 individuals) that 
included patients with attributes of the metabolic syndrome (one meta-analysis 
included). When associating healthy obese carriers, no association was 
observed in over 800 persons, while positive associations were found in over 
2,200 persons. Also, gender specific effects had been detected. In 467 women 
the variant had been positively associated with a higher BMI and related 
phenotypes. On the other hand, higher weight gain could be detected in male 
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but not in female carriers of the polymorphism. Literature search revealed no 
study observing histone modifications of PGC1α.  
Epigenetic modifications: Four studies reported on evidence for DNA 
methylation (table R12), while the literature search revealed no study on histone 
modification. DNA methylation of the promoter region in skeletal muscle and 
pancreatic cells from diabetics could be demonstrated to be increased 
compared to cells from healthy controls. A high fat diet and free fatty acids 
increased methylation even more.  
LPL 
Genetic polymorphisms: The LPL gene holds several polymorphisms. Three 
studies observed them with obesity phenotypes. Two different studies detected 
gender specific effects, each on a different SNP (rs320 and rs328) (summarized 
in table R13). 
Epigenetic modifications: Epigenetic evidence for the regulation of LPL revealed 
3 studies on DNA methylation and 3 studies on histone modifications (table 
R14). In adipose stem cells, DNA methylation in the promoter regions could be 
demonstrated. Furthermore, during adipogenesis, histone modification of the 
gene changes. Treatment of 3T3-L1 cultures with diallyl sulfide (a compound in 
garlic) results in decreased activity of HDAC which correlates with gene 
expressions. 
FABP4 
Genetic polymorphisms: One study observed the rs1054135 SNP in the gene of 
FABP4 in 309 subjects of mixed ethnicity and found a positive association with 
BMI (table R15). Epigenetic evidence for the regulation of LPL and FABP4 are 
summarized in tables R14 and R16. 
Epigenetic modifications: Epigenetic evidence for the regulation of FABP4 
revealed 3 studies on DNA methylation and 3 studies on histone modifications 
(table R16). In adipose stem cells, DNA methylation in the promoter regions 
could be demonstrated. Furthermore, during adipogenesis, histone 
modifications of the gene changes. Treatment of 3T3-L1 cultures with diallyl 
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sulfide (a compound in garlic) results in decreased activity of HDAC which 
correlates with gene expressions. 
Joint effects of observed polymorphisms 
Genetic association studies observing joint effects of polymorphisms are listed 
in tables R17 and R18. Carrier of the Pro12Ala variant in the PPARγ and the 
Trp64Arg variant in the ADRB3 gene had a higher BMI. Gender specific effects 
were detected for polymorphism rs320 in the LPL gene (independent of the 
simultaneous occurrence of the ADRB3 SNP (rs4994)). Most, but not all, 
reports suggest a synergistic effect of the variant in the UCP1gene and the 
ADRB3 variant.  
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DISCUSSION 
Aim of this work was to highlight the need for going beyond the scope in human 
genome epidemiology of complex traits and diseases. Therefore, in a case 
study of the metabolic syndrome, a pathway of adaptive thermogenesis had 
been chosen to demonstrate the great role of the epigenome on gene 
expression compared to SNP influence.  
Evidence for obesity associated SNPs & epigenetic 
modification 
During adipogenesis, enzymatic coordination of changes in histone modification 
and DNA demethylation in the promoter regions of PPARγ and C/EBPα are 
essential. If polymorphisms in these genes have effects on the activity of the 
transcription factors will have to be warranted in further studies. Previous 
studies have not been properly sized to detect effects. Although, a meta-
analysis is a powerful tool to confirm evidence, 19,600 subjects might still not be 
enough to draw a clear conclusion on the variants ability to increase the risk for 
developing Ob. Similar uncertainties remain with Trp64Arg (rs4994) in ADRB3 
and rs8192678 in the PGC1α. Meta-analysis reported big in-between study 
heterogeneity or did not distinguish between ethnic subgroups. The literature 
search did not reveal any study observing epigenetic modification in the 
ADRB3. I suggest future research focusing on epigenetic regulation of the 
ADRB3. More studies are also needed on effects of variations in the genes 
FABP4, LPL, and RXRα. The two PPARγ target genes, LPL and FABP4, are 
important factors in pathways ensuring steady substrate availability in 
mitochondria. Polymorphisms in the LPL gene probably influence the enzyme’s 
capacity to facilitate free fatty acids. Epigenetic regulation of PGC1α, FABP4, 
and LPL was demonstrated several times.  
Stimulation of the ADRB3 changes the epigenetic state of the UCP1 gene and 
facilitates it for transcription factors inducing expression. The A-3826G 
substitution of the UCP1 gene had been associated with reduced UCP1 mRNA 
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expression (Esterbauer, Oberkofler et al. 1998). Regardless, association 
studies represent no clear evidence on its contribution to Ob. These 
inconsistencies will have to be elucidated further. 
Current techniques allow simultaneous testing of many SNPs. A synergistic 
effect of the UCP1 and the ADRB3 polymorphisms could be detected if they 
reduced functions or expressions of the genes. Anyhow, by now, no study had 
appropriate sample sizes to detect differences. 
Characteristically shortcomings in human genome 
epidemiology 
General concerns in human genome epidemiology have already been 
discussed in previous chapters. Additionally to them, some interesting yet not 
discussed problems occurred and have to be mentioned. 
The re-evaluation of existing evidence has turned out to be an efficient and 
suitable approach to extract information from a great amount of small studies. 
Literature search revealed all together five meta-analysis in the genes PPARγ, 
ADRB3, and PGC1α. Each was reported to have big in-between study 
heterogeneity. Such heterogeneities make it difficult to synthesize information 
across studies in an appropriate way. 
The inconsistency in results of studies observing joint effects let suggest that 
traditional methods of building multiloci models simply fail to identify 
combinations.  
None of the studies reported any validation study. As previously discussed, they 
are a helpful tool to analyze uncontrolled bias. 
This review limited the search to Caucasians because SNP associations 
identified in one population are often not transferable to another population. 
Surprisingly, the comparison of results from studies on mixed ethnicities did not 
reveal any differences. Is this because there are no differences? Obesity is 
assumed to develop from a heterogeneous background, many different ways 
and environments involved. A profile describing a combination of risk factors is 
extremely unlikely to be found in more than one person. 
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Much more effort and money had been put into association studies of genetic 
variation than in observations of epigenetic variation. Though, the majority of 
observed polymorphisms could not be demonstrated to alter the network 
qualitatively.  
Characteristics in studies of epigenetic epidemiology 
Although, in epigenetic epidemiology high-throughput technologies already 
allow for the massive investigations of the epigenome, currently no consensus 
to the most appropriate way to model and present data exists. Approaches tend 
to be discovery-oriented rather than oriented to testing specific hypotheses. In 
studies revealed by the literature search, DNA methylation was merely 
measured at specific sites and hardly as the overall level of methylation pattern 
in a tissue. If DNA methylation was documented in detail, it was mostly referred 
to as % methylation of site. Histone modifications have been specified by 
histone number, position and modification. Some of the articles reported in- or 
decreased concentrations of specific histone modifying enzymes. 
Epigenetic modifications are able to regulate gene transcription in adaptive 
thermogenesis. How much environmental factors influence this part of the 
epigenome is still unclear. 
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CONCLUSION (I) CASE STUDY 
The results of the case study raise the question whether epigenetic 
mechanisms will explain the inconsistencies in human genome epidemiology. 
BAT content is highest in older infants and young children compared to preterm 
infants, stillborns, or human adults in whom WAT dominates (Lean, 1986). The 
less prominent role of thermogenesis in BAT in adult humans might be due to 
transcriptional downregulation of UCP1. A lesser activity of UCP1 is followed by 
more efficient energy coupling and lower metabolic rates – both predictors of 
weight gain (Cypess and Kahn). UCP1 deficient mice that are reared at room 
temperature gain weight faster than WT (Silva 2006) and obese humans have 
reduced expression of UCP1 mRNA down to 50 %. It is speculated that in adult 
humans, as little as 50 g of BAT could utilize up to 20% of basal caloric needs if 
maximally stimulated (Rothwell, Stock et al. 1983). If transdifferentiation from 
WAT to BAT was regulated by epigenetic mechanisms due to environmental 
influences, epigenetics could explain at least some of the inconsistencies 
between studies of human genome epidemiology on obesity. 
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CONCLUSION (II) FUTURE EPIDEMIOLOGIC STRATEGIES 
Network approaches 
An alternative to the forward genetics approach is the construction of molecular 
networks. In a system of multiple tissues, genetic, and environmental factors 
are acting together, the partitioning into component networks is able to increase 
the chance for elucidating variations in susceptibility to the phenotype. In recent 
studies the reconstruction of networks revealed how genetic variation, gene 
expression, and clinical traits may be combined and are able to explain causal 
associations between expression and disease traits (Schadt, Sachs et al. 2005; 
Chen, Zhu et al. 2008). These integrative approaches demonstrate the 
illumination of complex systems by incorporating multiple sources of information 
instead of considering each source independently. Integration of epigenetic data 
in discovery orientated approaches can reveal information that is not captured 
by previous observations. Figueroa et al combined epigenetic data with 
expression arrays in acute leukemia of distinct cell lineages. The analysis 
revealed hundreds of additional differentiated expressed genes that were 
missed by single-platform microarray studies. Furthermore, it enhanced the 
detection and statistical significance of biological pathways that were 
deregulated conditions (Figueroa, Reimers et al. 2008). 
Validating epigenetic markers 
The Human Epigenome project (www.epigenome.org/) aims to identify, 
catalogue and interpret tissue specific genome wide DNA methylation patterns. 
Markers are being classified by the type of variation (e.g. heritable) and by intra- 
and inter individual variants. Information o relationships (e.g. epigenotype – 
haplotype association) on the markers are of interest (Bjornsson, Fallin et al. 
2004) will have to be catalogued as well. Further, influences of time and other 
environmental factors (for example, nutritional compounds) will have to be 
analyzed systematically. In unraveling the histone code and the landscape of 
RNAs, such projects are still missing. 
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Animal models combine advances of genetic purity and environmental flexibility. 
Lately, a new approach was introduced to analyze large gene groups across 
species. It allows the identification of higher order systems of disease and 
phenotypes (Zhang, De et al.). Though, genetic or epigenetic variation has not 
been integrated yet, this method is a promising starting point to apportion 
findings from animal models if human tissue is unavailable. 
The annotation of validated epigenetic marker for gene maps will make it easier 
to assess the importance of including measured epigenotypes in gene 
discovery, or for evaluating the impact of time and environment on a genetic 
predisposition. 
Integrating epigenetic data to human genome epidemiology 
In a complex condition the knowledge of all genetic and environmental factors 
and of their interactions is required to explain the full etiology and identify 
subgroups. In 2008, Khoury et al (Rothman 2008) predicted a new level of 
complexity in epidemiology by simultaneously studying biomarkers of exposure, 
susceptibility, and outcomes. The integration of epigenetic markers into large-
scale population based studies that test for hypothesis in human genome 
epidemiology could be a solution for the problems of incomplete penetrance 
and variable expressivity. 
The common disease genetic and epigenetic (CDGE) model (figure 4) overlies 
the ‘common genetic variant, common disease’ hypothesis with an epigenetic 
component interacting. It will be helpful when designing such a study in the 
future (Bjornsson, Fallin et al. 2004). 
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Figure 4 The CDGE model demonstrates factors (genetic, environmental, stochastic) 
contributing to epigenetic variation, epigenome and genome interacting indirectly and 
the environments influence on the disease. In some cases the epigenome will not 
influence the disease (DNA genotypes independent). It provides a starting framework 
for including epigenetic marker in epidemiologic studies. 
Study designs 
Unlike genetic variants, epigenetic and other markers cannot be seen as stable 
indicators of host susceptibility. On the one hand, diseased populations are a 
rich source for molecular phenotype data, while on the other hand, cohorts have 
been obtained and stored biologic specimens since decades and are interesting 
for genetic association studies (Langholz, Rothman et al. 1999). A “meet in the 
middle approach” emphasizes the complementarity between different types of 
markers and study designs and has the potential of simultaneous testing of 
markers of multiple levels (Vineis and Perera 2007). If population based, 
designs have the important advantage to provide estimates of absolute risk and 
population attributable risk in addition to estimates of relative risk (Khoury, Little 
et al. 2004). 
Data analysis 
With information on genotypes, molecular profiles and clinical information 
collected from large-scale populations will generate many data points for each 
sample. The complexity in data analyzes poses novel statistical challenges, 
including an increased likelihood to produce false-positive results. (Boffetta) 
Approaches of pharmacological dose-response studies will be useful (Conti, 
Cortessis et al. 2003). Also, stochastically models in carcinogenesis describing 
Environment 
Age 
Parental epigenotype 
DNA genotypes 
Parental environment 
 
Disease 
DNA genotypes independent  
DNA genotypes dependent  
Epigenotype  
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the relationship of time, exposure and response are a good starting point. 
Furthermore, clustering approaches, or networks for analyzing complex 
molecular and genetic datasets will become increasingly interesting (Zhang, De 
et al.). 
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CONCLUSION (III) GENETIC TESTING & PUBLIC HEALTH 
Consumer orientated genetic testing 
The ‘common disease – common variant hypothesis’ postulates that the genetic 
influence on the susceptibility to common diseases is attributable to a limited 
number of variants present in more than 1% to 5% of the population. For 
instance, one of the first GWAs on age-related macular degeneration identified 
five major variants. Each variant is associated with a two to three times the risk 
for a person to develop the disease (Manolio). These positive associations 
could be replicated easily. Most common conditions have not been as 
amenable to investigate and results cannot be effectively translated into risk 
assessments and preventive health policies at present. Patients who acquire 
genomewide association testing should be advised that as of yet, the majority of 
results have no value in predicting risks and have no clinical direction. 
Increasing the predictive value 
A large number of biomarkers for exposure, absorption, metabolism, 
distribution, critical target interaction (i.e., DNA damage and repair), genetic 
changes, and disease have been revealed by epidemiologic research. The 
combined use of genetic and molecular profiles with clinical data provides more 
convincing results. Epigenetic key drivers with disease-specific occurrence 
could easily be combined with environmental risk factors and genetic 
susceptibility variants. Other epigenetic markers are unbiased information when 
assessing environmental influences. Integrating such biomarkers in genetic 
testing would increase their predictive value (Burke, Atkins et al. 2002) (Schadt, 
Sachs et al. 2005). 
Challenges for public health 
Today, without regards to inter-individual variations, results from previous 
epidemiologic investigations are applied to entire populations. In almost every 
population studied, a degree of disease heterogeneity is present indicating the 
mixture of different subtypes of the disease. With respect to a disease 
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phenotype, individuals may appear similar but underlying molecular processes 
vary widely between individuals. This dispels the “one-drug-fits-all” view and 
explains the lack of success of many intervention programs. 
Human genome epidemiology has got the potential to unravel the 
heterogeneous etiologies of common complex diseases. Increasing sensitivity 
and specificity of epidemiological studies will help to detect different levels of 
diseases and to identify subgroups. Guidelines and recommendations for the 
evaluation and integration of data from human genome epidemiology have 
already been published (Burke, Atkins et al. 2002). Rothman et al further 
suggested an ethical duty of granting agencies and editors to require a thorough 
quantitative assessment of relevant literature and their systematic errors 
(Rothman 2008). 
By now, genotype prevalence data is not concrete enough to work with on a 
population-level. A view from inter-individual levels offers opportunities for 
understanding the relationship between cumulative exposures and population. 
Public health will have to deal with the meaning of altered levels of biomarkers 
at an individual level. Such powerful tools for risk assessment provide the ability 
for stronger prevention strategies in the future.  
The importance of following good epidemiologic practice and implementing 
rigorous quality assurance and control procedures cannot be overstated and 
helps to guarantee the successful integration of genetic tests and services into 
the health care system. Accurate reporting will allow the evaluation of new tests 
with the assurance that decisions are based on the available evidence. For 
instance, the “Screening Brief” featured in the Journal of Medical Screening 
could be applied to genetic tests, or the Human Genome Epidemiology reviews 
which are a regular feature in the American Journal of Epidemiology (Burke, 
Atkins et al. 2002). 
In the United States, the National Genomic Applications in Practice and 
Prevention (EGAPP) Initiative was established to support the development and 
implementation of an evidence-based process for evaluating genetic tests and 
other genomic applications for clinical and public health practice. (Teutsch, 
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Bradley et al. 2009). Such initiatives will also need to develop guidelines (e.g., 
clinical guidelines) with respect to differences in health care priorities and 
resources in different health care settings (Burke, Atkins et al. 2002) for a 
scientifically tenable integration of genetic testing into the health care system. 
  
79 
 
 
SUMMARY 
A complex trait consists of the interplay of several networks, tissues, and 
environments. The Epigenome includes all mechanisms and marks that alter 
chromatin without changing the DNA sequence. It is tissue and cell-type specific 
and varies as a function of time, environmental factors, and random processes.  
Human genome epidemiology offers frameworks for understanding joint impacts 
of genes and environments regarding disease risk. Genome-wide association 
studies have identified many genetic variations and provided insights into the 
genetic architecture of diseases. However, modest effect sizes of common 
mutations and inadequate power to overcome the heterogeneity of genetic 
effects could not be revealed by stringent genome wide significance thresholds.  
This work approached epigenetic influence on transcriptional regulation in a 
case study on adaptive thermogenesis and obesity on a network level. Results 
from a systematic literature search were compared to research findings from 
genome association studies on SNPs common in Caucasians. Whether these 
polymorphisms diminish energy expenditure remains unclear and has to be 
warranted in further studies. Altogether, the results of the analysis let suggest 
that hereditary genetic- and environment responsive regulation is involved. 
Integration of epigenetic markers in epidemiologic research could thus help to 
unravel multi-gene-environment interactions in the development of obesity. 
Future research strategies that simultaneously study biomarkers of exposure, 
susceptibility, outcomes in appropriately planned, designed, and conducted 
studies will extend beyond current approaches. Nevertheless, sample size 
requirements remain an inescapable challenge. The integration of epigenetic 
markers in genetic testing should increase their predictive value for complex 
diseases with public health importance. Effective organization is vital for  
disseminating genetic tests to the health care system.  
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ZUSAMMENFASSUNG 
Komplexe Krankheiten zeichnen sich durch das Zusammenwirken mehrerer 
genetischer und umweltbedingter Faktoren aus. In der Epigenetik werden 
Veränderungen des Chromatins untersucht, welche die DNA Sequenz nicht 
verändern jedoch auf Umweltfaktoren und Alterungsprozesse reagieren und 
somit die Genexpression beeinflussen.  
Moderne epidemiologische Forschung versucht Möglichkeiten zu entwickeln um 
komplexe Gen-Umwelt Interaktionen zu verstehen. In der Vergangenheit 
konnten in Genom-weiten Studien einige bahnbrechende Erfolge erzielt 
werden. Trotzdem gab es bisher noch keine zufriedenstellenden Ansätze um 
ständig wiederkehrende Probleme zu lösen. Zu den Schwierigkeiten zählen die 
oft kleinen Effekte einzelner Polymorphismen, die heterogene Ätiologie einer 
komplexen Krankheit und zu kleine Studiengrößen um Effekte zu detektieren. 
Eine vielversprechende Herangehensweise ist die gleichzeitige Untersuchung 
epigenetischer und genetischer Marker. 
In dieser Arbeit wurde ein Netzwerk der adaptiven Thermogenese gewählt in 
dem das Zusammenspiel von Umwelt und Genetik klar ersichtlich ist. Die 
Ergebnisse einer systematischen Literatursuche sowohl nach 
Assoziationsstudien als auch nach Studien epigenetischer Modifikationen 
ergaben, dass Epigenetik eine nicht zu vernachlässigende Rolle spielt, 
wogegen die Studien an Polymorphismen keine klare Evidenz für deren 
Beteiligung an der Entstehung von Übergewicht lieferten. 
Zukünftige Forschungsansätze in gewissenhaft geplanten Studien werden 
verschiedene Biomarker einsetzen müssen. Jedoch stellen auch hier die 
Studiengrößen weiterhin ein Problem dar. Den Erfordernissen eines modernen 
Public Health Sektors dies dienlich sein. 
Des Weiteren haben validierte epigenetische Marker großes Potential zur 
Steigerung der Prognosesicherheit genetischer Tests. 
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ATTACHED MANUSCRIPT: SYNERGISM OF GENETIC AND 
EPIGENETIC VARIATION IN THERMOGENESIS 
ABSTRACT 
Background: Complex traits are characterized by several different pathways 
where multiple genetic and environmental factors interact. Epidemiologic 
research has been facing severe limitations in unraveling complex conditions 
when focusing either on genetic or environmental factors. As a result of many 
genome wide association studies a missing heritability has been discussed and 
epigenetic factors are considered to explain gene-environment interactions.  
Objective: The example of adaptive thermogenesis in obesity was analyzed to 
demonstrate synergisms of genetic and epigenetic regulation in obesity. 
Method: A systematic literature search was done for genetic and epigenetic 
variation of genes involved in adaptive thermogenesis: gens included beta-3 
adrenergic receptor (ADRB3), uncoupling protein 1 (UCP1), lipoprotein lipase 
(LPL) and fatty acid binding protein 4 (FABP4) and the transcription factors 
peroxisome proliferated activator receptor gamma (PPARγ), peroxisome 
proliferated activator receptor gamma coactivator 1 alpha (PGC1α), 
CCAAT/enhancer-binding protein alpha (C/EBPα), and retinoid acid X receptor 
alpha (RXRα). 
Results: SNPs as well as epigenetic mechanisms seem to regulate adaptive 
thermogenesis. Genetic association studies had serious problems of 
inconsistencies with results. Studies of epigenetic evidence were discovery 
orientated rather than hypothesis testing but demonstrate existing epigenetic 
modulation in obesity and adaptive thermogenesis.  
Discussion: Results from this analysis suggest that hereditary genetic- and 
environment responsive regulation is involved in adaptive thermogenesis. The 
integration of epigenetic markers in epidemiologic research could thus help to 
unravel multi-gene-environment interactions. They also should have the 
potential to increase the predictability of genetic testing for complex diseases 
with public health importance. 
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INTRODUCTION 
Epidemiologic research of complex interactions 
In developed countries complex diseases make up the majority of morbidity and 
mortality (Zhang, De et al.). They are characterized by the joint effects of 
multiple genes and multiple environmental factors in different pathways and 
networks. Genetic variations identified so far, only explain a small proportion of 
the heritability of complex conditions. Furthermore, the replication of results has 
turned out to be more challenging than expected (Hirschhorn, Lohmueller et al. 
2002) (Ioannidis 2005). Genetic association studies often carry only limited 
information about environmental exposures or other non-genetic risk factors. In 
the presence of such unknown etiologic factors it is difficult to unravel 
interactive partners and joint effects (Pearson and Manolio 2008). In a complex 
disease, the knowledge of all genetic and environmental factors and their 
complex interactions might be required to explain the full etiology. But even if 
the exact combination of factors that contributed to a disease phenotype has 
been identified in one person, it is unlikely that this etiologic profile fits another 
person. Such heterogeneous etiologies make it even more difficult to identify 
interactions between the environment and genes or environmental modifications 
of genotype associations. 
Epigenetics 
Epigenetics studies heritable changes in gene expression that are due to 
altered chromatin without changing the DNA sequence and it offers promising 
tools to unravel inconsistencies in human genome epidemiology (Bjornsson, 
Fallin et al. 2004) (Dolinoy and Jirtle 2008) (Figueroa, Reimers et al. 2008) 
(Foley, Craig et al. 2009). Epigenetic modifications vary with several 
environmental influences and can be stably passed over numerous cycles of 
cell division (Jablonka and Raz 2009). Some alterations can even be inherited 
from one generation to the next. They have been suggested to form an 
alternative, “soft inheritance” system (Jablonka and Raz 2009). The ‘‘fetal basis 
of adult disease hypothesis’’ postulates that environmental influences during 
prenatal and early postnatal development model cellular plasticity, thereby 
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altering susceptibility to adult diseases like cardiovascular disease, type 2 
diabetes, and (the metabolic condition) obesity (Ob) (Dolinoy and Jirtle 2008). 
The most prominent example is that of the agouti mouse model where maternal 
dietary genistein supplementation during gestation results in hypermethylation 
of an upstream promoter region of the Agouti gene in the offspring. This 
epigenetic marker persists into adulthood and protects offspring from obesity 
(Dolinoy and Jirtle 2008). 
The Epigenome is the overall epigenetic state of a cell including all mechanisms 
and marks such as non-coding RNAs, the histone code, and DNA methylation. 
The latter is the covalent addition of a methyl group to a cytosine that precedes 
a guanosine in the DNA sequence (the CpG dinucleotide) and is a dynamic 
marker of the transcriptionally repressed gene (Bird 2002). Histone 
modifications result in different transcriptional outcomes depending on type, 
amount, site of modification and its reversibility (reviewed in (He and Lehming 
2003). 
Genetics & Epigenetics in Obesity 
In humans, Ob is defined as body mass index (BMI) >30 kg/m2 and works as a 
major risk factor for common chronic diseases such as diabetes, diseases of 
the cardiovascular and musculoskeletal system, and some cancers (Haslam 
and James 2005). It is characterized by an excessive accumulation of lipids in 
body cells, markedly in adipocytes and mostly results form an imbalance 
between energy intake and expenditure (obesogenic environment). The 
regulation of body fat content results from an integrative network influenced by 
the central nervous system, the gastrointestinal tract, the adipose tissue itself 
and skeletal muscles in responses to multiple nutrient, drug, toxin, sensory and 
hormonal inputs. Further it is influenced by circadian rhythm and physical, gut 
and social environments. For instance, pathways in energy homeostasis, 
adipogenesis and hormonal signaling, have been suggested to contribute to the 
development of Ob. In 2006 the last update of the Obesity Gene Map Database 
summarized positive associations for DNA sequence variation with Ob 
phenotypes in 127 candidate genes. Among them (those showing replications in 
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at least 10 studies) have been: PPARG (30 studies), ADRB3 (29), ADRB2 (20), 
LEPR (16), GNB3 (14), UCP3 (12), ADIPOQ (11), LEP (11), UCP2 (11), 
HTR2C (10), NR3C1 (10), and UCP1 (10) (Rankinen, Zuberi et al. 2006). Since 
then, many more loci have been identified, but they still account for little of the 
heritability, often less than 1 % (Speliotes, Willer et al 2010) (Heid, Jackson 
2010). 
Ob is expected to develop from a heterogeneous background. That means, with 
respect to all cases in an obesogenic environment, in any individual with the 
obese phenotype, only one or a subset of these pathways might be involved. So 
in other words, in the same obesogenic environment individuals with different 
gene combinations might be equally well adapted (Manolio). Additionally, 
associations between polymorphisms and phenotypes tend to have modest 
effects with effects less than OR = 2. Such variations rather tend to induce a 
shift in between the working capacities of the networks influencing the 
development of Ob. On the other hand, epigenetic programming adjusts the 
phenotype without integrating the genetic determination of the trait. Extreme 
environmental conditions, postnatal and during early life, lead to an 
establishment of the trait further away from the genetically determined (Stoger 
2008). During the entire life diet, lifestyle factors, maternal behavior, air 
pollution, toxins, and other environmental factors may modify the epigenome 
and contribute to the development of Ob (Haslberger 2010). This developmental 
plasticity allows the development of a range of phenotypes from a single 
genotype. 
The Network of adaptive thermogenesis in BAT 
Energy balance is crucial for constant body weight, strongly depends on the 
work of the skeletal muscle, and is a main element in the development of Ob. 
Also, adaptive thermogenesis in brown adipose tissue (BAT) dissipates energy 
in the respiratory chain due to the oxidation of fatty acids (Silva 2006). BAT’s 
thermogenic activity depends on the degree of stimulation by the sympathetic 
nervous system and the amount of uncoupling protein 1 (UCP1) in the inner 
mitochondrial membrane which uncouples respiration from ATP synthesis to 
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produce heat (Silva 2006). Less activity of UCP1 results in a more efficient 
energy coupling and lower metabolic rates, both predictors of weight gain. 
(Cypess and Kahn) UCP1 deficient mice are cold intolerant, but surprisingly not 
ob. When fed with a high-fat diet, they gain less weight than wild type (WT) 
controls. This Ob resistance is ambient temperature dependent because when 
reared at room temperature deficient mice gain weight faster than WT (Silva 
2006). Downregulation of UCP1 expression in adult humans might result in its 
less prominent role of thermogenesis in BAT (Silva 2006). In obese persons a 
reduced expression of UCP1 mRNA down to 50 % was demonstrated. During 
the last few years, studies have revealed a sort of a transdifferentiation from 
adult white to brown adipocytes with similar morphology and that might be due 
to epigenetic regulation (Barbatelli, Murano et al.). 
The UCP1 gene holds (among other regulatory elements) a response element 
for the orphan nuclear receptor family of peroxisome proliferated activator 
receptors (PPARs). PPARγ is a member of these transcription factors and acts 
as sensor for a variety of lipids and lipid like compounds (e.g. ω-3 fatty acids). 
Different promoters in the gene and alternative splicing result in several 
isoforms. For instance, PPARγ2 is expressed exclusively in adipose tissue 
while PPARγ1 can also be found in liver and other tissues (McClelland, 
Shrivastava et al. 2009). Ligand binding to the receptor initiates the gene 
transcription process through conformational changes, a heterodimerization 
with the retinoid acid X receptor alpha (RXRα) and the assembly with 
coactivators to a multiprotein complex (Kliewer, Umesono et al. 1992). PGC1α 
acts as a ligand-independent coactivator for PPARs and is expressed 
preferentially in BAT. Histone acetylase (HAT) activity of coactivators leads to a 
modification of the chromatin structure of the proximate DNA which allows the 
large complex to bind to a respond element and to initiate transcription. In the 
absence of ligands, a PPAR interacts with corepressor proteins and builds a 
complex with histone deacetylases (HDACs) which results in a locally more 
compact chromatin packaging (Li, Pascual et al. 2000). The binding of the 
PPARγ2/RXRα/PGC1α complex to the respond element of UCP1, followed by 
its transcriptional activation, have been demonstrated to be essential in brown 
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adipogenesis (Barak, Nelson et al. 1999). Other PPARγ target genes are, for 
example, the extracellular lipoprotein lipase (LPL) which mediates the uptake of 
fatty acids into the cell (Wang and Eckel 2009), and the fatty acid binding 
protein 4 (FABP4) which is expressed exclusively in adipocytes and 
macrophages. Although the role of this fatty acid carrier protein is not yet well 
understood, its function could be correlated to lipid metabolism (Shin, Li et al. 
2009). 
Another essential transcription factor in adipogenesis is CCAAT/enhancer-
binding protein alpha (CEBPα) whose target genes are LPL and ADRB3, 
among others (Rosen and Spiegelman 2006). For rapid adjustment the ADRB3 
in BAT is targeted by catecholamines in response to cold (Silva 2006). The 
activation of the receptor signaling results in an increased expression of the 
PGC1α gene (Cao, Daniel et al. 2004). 
The capacity of this network strongly depends on environmental influences. 
Fatty acids are the only substrate for oxidative phosphorylation in BAT and act 
as ligands of the nuclear receptor PPARγ. RXRα is a high affinity nuclear 
receptor for 9-cis retinoic acid, a metabolite of retinoic acid. Increased 
uncoupling of the respiratory chain from ATP production depends on the 
activation of the ADRB3 in response to cold (Silva 2006). 
METHOD 
In a systematic literature review information was screened for in most frequently 
observed SNPs in genes involved in adaptive thermogenesis (table 1) in 
Caucasians. The literature search revealed observational studies associating 
the polymorphisms with anthropometric measurements and related ob 
phenotypes. We included studies reporting observations on Caucasians and 
mixed ethnicities. If no ethnicity was reported, a study was included if it was 
conducted in central Europe and it could be assumed to include Caucasians. 
Evidence for epigenetic regulation of the same genes was searched in the 
same way by using the terms “gene” and/or “gene name” and “epigenetic” 
and/or “methylation” in title and/or abstract. Additionally, reference lists from 
articles were searched for further suitable studies. English publications that 
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gave sufficient information on DNA methylation and histone modifications in the 
genes were summarized. No other variations (e.g. frame shift mutations or copy 
number variations) than selected SNPs and no other data on posttranscriptional 
modification than epigenetic modifications have been included. 
Table1 genes under observation 
Gene name Gene Gene map 
locus 
SNP 
Beta-3 adrenergic receptor ADRB3 8p12-p11 rs4994 
CCAAT/enhancer-bindingproteinalpha CEBPα 19q13 rs12691 
rs41490344 
rs41504144 
rs41344151 
rs16967952 
rs34508287 
rs41428545 
rs34529039 
rs41367646 
rs1049969 
rs707656 
Fatty acid binding protein 4 FATBP4 8q21 rs1054135 
Lipoprotein lipase LPL 8p22 rs285 
rs320 
rs328 
Peroxisome proliferated activator receptor 
gamma coactivator 1 alpha 
PGC1α 4p15 rs8192678 
Peroxisome proliferated activator receptor 
gamma 
PPARγ 3p25 rs1801282 
Retinoid acid X receptor alpha RXRα 9q34 - 
Uncoupling protein 1 UCP1 4q31 A-3826G 
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RESULTS 
The Pro12Ala (rs1801282) is one of the most prominent SNPs in the PPARγ 
gene. It has been observed for associations with phenotypes of the metabolic 
syndrome for many years. The literature research revealed a meta-analysis that 
included over 19,600 subjects and positively associated the Ala variant with 
increased BMI (table R1).  
In adipocytes the correct epigenetic modification of the promoter region in the 
PPARγ gene seems to be essential during cell differentiation and for the 
maintenance of the adult state of the cell. In tables R2 and R3, studies 
observing epigenetic regulations of the gene are summarized. In cells from a 
human umbilical cord where PPARγ2 is not expressed, its promoter region is 
hypermethylated. In human gastric mucosa cells of ulcer and cancer patients, 
hypomethylation of the promoter region was observed which concurs with 
findings from cancer research where cancerous cells become globally 
hypomethylated and tumorsuppressor genes hypermethylated (Esteller 2008). 
In human adipose stem cells the promoter region is hypomethylated and 
gradually demethylated upon induction of differentiation in 3T3-L1 cultures. 
Furthermore, in lean mice, promoter methylation was increased when compared 
to that of ob mice. The results from studies observing histone modifications give 
a similar picture: during adipogenesis enzymatically coordinated deacetylation 
and methylation events at sites on H3 and H4 facilitate the transcription of the 
gene and have been replicated by several groups (R3). 
The search for RXRα, the heterodimerization partner of PPARγ, has not 
revealed sufficient literature to draw a clear conclusion for its susceptibility to 
contribute to the development of Ob. When screening the gene for DNA 
variants, Hegele et al  identified 3 common variations in Caucasians: -25 A>G, 
69 G>A, and 1470 C>T (Hegele and Cao 2001). Though, this receptor plays a 
key role in development and metabolism, no study associated any genetic 
variation with Ob traits. The search for epigenetic evidence in the gene revealed 
only one study examining the effects of green tea on demethylation of the 
promoter region in cancerous mice (Volate, Muga et al. 2009). 
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The C/EBPα gene holds several polymorphisms that have been associated with 
different types of cancers. Their contribution to Ob have been under study by 
only two groups (table R4). Evidence for epigenetic regulation of the gene exists 
as well. Heterogeneous responses to inhibitors of histone and DNA modifying 
enzymes demonstrate that both mechanisms are involved in the transcriptional 
regulation of the gene (tables R5 and R6). C/EBPα is incapable of a direct 
interaction with DNAmethyltransferases (Hervouet, Vallette et al. 2009) but 
several studies demonstrated that a C/EBPα-HDAC complex is able to silence 
several protein coding genes due to aging (Jin, Wang et al. 2009). One of 
C/EBPα’s target genes is ADRB3. Studies observing the SNP Trp64Arg 
(rs4994) and its association with Ob are summarized in tables R7 and R8. The 
last meta-analysis, published in 2008, summarized 53 studies in Caucasians 
and had an overall size of about 23,000 individuals. No positive association/s 
could be detected. Since then, further studies have been published associating 
the SNP with Ob (table R8). Seven studies with an overall all size of 8,323 
subjects did not detect an effect, while 4 studies (1,267 subjects) did find 
positive associations. Searching for epigenetic evidence did not reveal any 
studies of the ADRB3 gene itself. However, the stimulation of the receptor 
induces the expression and recruitment of a demethylase to the promoter of the 
UCP1 gene and facilitates the ability of PPARy, RXRα and their co-activators to 
bind to the response element on the DNA.  
Groups observing genetic variation in the UCP1 gene merely focused on the A-
3826G substitution (table R9). The gender specific effect observed by two 
groups (total 701 women) could not be replicated by two other groups (total 77 
women). As well, in a study including 722 men no effect had been detected. 
Furthermore, eleven studies with an overall size of 4,466 subjects could not 
positively associate the polymorphism with Ob, even though 3 studies (all 
together 557 subjects) did.  
Observations of DNA methylation and histone modifications (table 10) of the 
promoter region in several different tissues revealed tissue specificity. This 
reflects previous observations of the epigenome (Esteller 2008). In 3T3-L1 
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cultures gene silencing by DNA methylation and repressive histone 
modifications were demonstrated by different groups. 
The coactivator PGC1α holds the SNP rs8192678 that changes the amino acid 
sequence at position 482 from glycin to serin. It is the most examined 
polymorphism in the gene in relation to Ob. The studies revealed by literature 
are summarized in table R11. No effect of the variant was detected by studies 
(all together 16,000 individuals) that included patients with attributes of the 
metabolic syndrome (one meta-analysis included). When associating healthy 
obese carriers, no association was observed in over 800 persons, while positive 
associations were found in over 2,200 persons. Also, gender specific effects 
had been detected. In 467 women the variant had been positively associated 
with a higher BMI and related phenotypes. On the other hand, higher weight 
gain could be detected in male but not in female carriers of the polymorphism. 
An observation that focused on histone modifications of the PGC1α was not 
detected. DNA methylation of the promoter region in skeletal muscle and 
pancreatic cells from diabetics could be demonstrated to be increased 
compared to cells from healthy controls. A high fat diet and free fatty acids 
increased methylation even more. In table R12 findings from the literature 
search are listed. 
The LPL gene holds several polymorphisms. Two different studies observed 
gender specific effects, each on a different SNP (rs320 and rs328) (summarized 
in table R13). One study observed the rs1054135 SNP in the gene of FABP4 in 
309 subjects of mixed ethnicity and found a positive association with BMI (table 
R15). Epigenetic evidence for the regulation of LPL and FABP4 are 
summarized in tables R14 and R16. In adipose stem cells DNA methylation in 
both promoter regions could be demonstrated. Further, histone modifications of 
each gene change during adipogenesis. Treatment of 3T3-L1 cultures with 
diallyl sulfide (a compound in garlic) results in decreased activity of HDAC 
correlating with gene expression of both, LPL and FABP4. 
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Observed joint effects of SNPs 
Genetic association studies observing joint effects of polymorphisms are listed 
in tables R17 and R18. No matter of ethnicity, carrier of both, the Pro12Ala 
variant in the PPARγ and the Trp64Arg variant in the ADRB3 gene had a higher 
BMI. Gender specific effects were detected for the polymorphism rs320 in the 
LPL gene (independent of the simultaneous occurrence of the ADRB3 SNP 
(rs4994)). Most, but not all, reports suggest a synergistic effect of the variant in 
the UCP1gene and the ADRB3 variant.  
DISCUSSION 
Discussion network: SNPs vs. epigenetic evidence 
In adipogenesis, the enzymatic coordination of changes in histone modification 
and DNA demethylation in the promoter regions of PPARγ and C/EBPα are 
essential. If genetic variations have effects on their activities as transcription 
factors will have to be warranted in further studies. Previous studies have not 
been properly sized to detect little effects. Although, a meta-analysis is a 
powerful tool to confirm evidence, 19,600 subjects might still be not enough to 
draw a clear conclusion. Similar uncertainties remain with theTrp64Arg (rs4994) 
in ADRB3 and the SNP (rs8192678) in the PGC1α. Meta-analysis reported big 
in-between study heterogeneity or did not distinguish between ethnic 
subgroups. The literature search did not reveal any study observing epigenetic 
modification in the ADRB3. We believe that future epigenetic research will have 
to focus more on the ADRB3 gene as it is an interesting candidate in the field. 
Further observations on genetic variations are also needed for FABP4, LPL, 
and RXRα. The two PPARγ target genes, LPL and FABP4, are important 
factors in pathways ensuring the steady substrate availability for mitochondria. 
Polymorphisms in the LPL gene probably influence the enzyme’s capacity to 
facilitate free fatty acids. Epigenetic regulation of PGC1α, FABP4, LPL, and 
RXRα could be demonstrated several times. Stimulation of the ADRB3 changes 
the epigenetic state of the UCP1 gene and facilitates it for transcription factors 
to induce expression. The A-3826G substitution of the UCP1 gene had also 
been associated with reduced UCP1 mRNA expression (Esterbauer, Oberkofler 
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et al. 1998). Although, it is a promising candidate for an Ob susceptibility 
variant, findings do not show clear evidence for associations with Ob 
phenotypes. These inconsistencies will have to be elucidated in further 
research. 
Current techniques allow the simultaneous testing of many SNPs. A synergistic 
effect of the UCP1 and the ADRB3 polymorphisms could occur if the functions 
or expressions of the genes were reduced. But by now, no study had the 
appropriate sample size for reliable findings. 
Limitations of summarized epidemiology 
Much more effort and money had been put into association studies of genetic 
variation than in observations of epigenetic variation. Though, evidence for 
epigenetic mechanisms potentially shaping the network capacity is strong. The 
majority of observed genetic polymorphisms have not shown qualitative 
alterations in the network yet. This is a well-recognized problem in the 
community of human genome epidemiologists. Often, the excitement about a 
strong first finding is followed by inconsistencies (Ioannidis 2005). The general 
lack of reproducibility has been attributed to some serious problems like the 
heterogeneity of disease etiology, limitations in study designs, massive amount 
of errors, bias and confounder decreasing statistical power, and many problems 
in data analysis (Khoury 2004) (Pearson and Manolio 2008) (Manolio). A big 
challenge, especially when observing complex traits, are interactions between 
multiple genetic and environmental factors which raise problems of cost 
effective sample size requirements (Khoury 2004). Till now, the approaches in 
epigenetic epidemiologic studies tend to be discovery-oriented rather than 
oriented to testing specific hypotheses. And although high-throughput 
epigenetic technologies already allow massive investigations of the epigenome, 
there is still no consensus to an appropriate way to model and present data. 
This problem has already been discussed by (Foley, Craig et al. 2009) and has 
not changed till now. The epigenome probably accounts for some of the 
heritability not explained by previous and current human genome epidemiologic 
approaches and holds measurable and unbiased markers for investigations. In 
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the Human Epigenome project (www.epigenome.org), tissue specific genome 
wide DNA methylation patterns are identified, catalogued and interpreted. 
Marks are already being classified by the type of variation (e.g. heritable) and 
by intra- and inter individual variations. In a next step, information of 
relationships (e.g. epigenotype – haplotype association) will have to be 
examined (Bjornsson, Fallin et al. 2004). Similar efforts are being made for the 
histone code and miRNAs and will allow for assessing the importance to include 
epigenotypes in gene discovery, or for evaluating the impact of time and 
environment on a genetic predisposition. Integration of epigenetic data in 
discovery orientated approaches can reveal information that is not captured by 
previous observations as demonstrated by Figueroa et al in acute leukemias of 
distinct cell lineages. By combining epigenetic data with expression arrays, the 
analysis revealed hundreds of additional differentiated expressed genes that 
were missed by single-platform microarray studies and it also enhanced the 
detection and statistical significance of biological pathways that were 
deregulated in the conditions (Figueroa, Reimers et al. 2008). An integrative 
approach has promising solutions in cases of incomplete penetrance and 
variable expressivity of complex diseases. 
CONCLUSION 
We selected a molecular network in BAT which is under strong environmental 
influences. Current knowledge of SNPs in the network does not reveal 
conclusive information, while epigenetic regulation clearly influences the 
network’s thermogenic capacity. Evidence for the contribution to Ob will have to 
be warranted in both epigenetic and genetic epidemiology. 
In such a complex condition, genetic and environmental factors will have to be 
observed simultaneously using unbiased methods. Therefore, tools of 
epigenetic epidemiology might be helpful. The integration of validated 
epigenetic biomarkers into databases will make it easier to assess the 
importance of including measured epigenotypes in gene discovery or for 
evaluating the impact of time and environment on a genetic predisposition. 
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In 2008, Khoury et al (Rothman 2008) predicted a new level of complexity in 
epidemiology by simultaneously studying biomarkers of exposure, susceptibility, 
and outcomes. High-throughput methods and innovative approaches for 
analyzing big amounts of data are making this easier (Figueroa, Reimers et al. 
2008) (Zhang, De et al.). Epigenetics is a promising feature to expand the 
scientific frontiers on etiology, disease risk prediction and prevention of health 
threatening conditions.  
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